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ABSTRACT 
 
Vaccines have diminished the burden and spread of infectious diseases by inducing 
protection against pathogens hence reducing disability and mortality. The success of 
standard methods of vaccination, such as immunizations with live attenuated vectors, relies 
on the recognition of microbial components by the innate immune system, which in turn 
influences the response of the adaptive immune system in order to eradicate the pathogen. 
However, safety concerns associated with live attenuated vectors prevented their wide 
application. As a consequence, subunit vaccines, composed of microbial components and 
proteins, have emerged to elicit protective immunity, thus offering a more simplified, safer 
and standardized mode of immunization. 
Single components, such as proteins and immunostimulatory agents (adjuvants) are not as 
immunogenic as whole pathogens, and thus there is a need for novel strategies to enhance 
their immunogenicity. Nanoparticle carriers (<1000 nm) are a promising mean of protein and 
adjuvant delivery, since they enhance immune responses by protecting the antigen from 
early degradation, promoting antigen retention in lymphoid organs and allowing dendritic cell 
(DC) targeting in lymphoid organs.  Considering the efficacy of nanoparticle-based systems 
for vaccination, our laboratory has recently developed two delivery platforms based on 
poly(ethylene glycol) (PEG) and poly(propylene sulfide) (PPS): nanoparticles (NPs) and 
polymersomes (PSs) differ in size, method of antigen loading and method of antigen release. 
In this thesis, we evaluated the impact of antigen delivery by nanocarriers on the magnitude, 
and more importantly, on the quality of cellular and humoral responses.  We first assessed 
how NPs modified the CD8+ T cell response to a viral MHCI epitope and demonstrated that 
presentation by NPs can significantly enhance the magnitude of the cellular response. Next, 
we asked how the quality of the cellular response differed from a standard method of 
immunization, a DC-based vaccine.  We showed that the quality of the memory CD8+ T cells 
was considerably altered, with NPs promoting a robust pool of memory CD8+ T cells with an 
effector-like phenotype characterized by high expression of KLRG-1 and low expression of 
CD43, CD27 and CD62L. By contrast, DC vaccination promoted a central memory-like 
phenotype. 
Recent work by our group showed that T cell responses induced by NPs and PSs differ 
significantly depending on the delivery vehicle, with NPs enhancing cytotoxic T cell 
responses and PS augmenting CD4+ T cells. Herein, we demonstrated that the preferential T 
cell activation is a consequence of distinct intracellular trafficking and differential organ 
biodistribution of the antigen, which is promoted by the properties of the nanocarrier. 
Furthermore, we found that PSs are better at enhancing CD4+ T cell activation and inducing 
T follicular helper (Tfh) cells, which translated in an increase in germinal center B cells, which 
is beneficial for the development of vaccines based on humoral responses.  Based on these 
results, we decided to evaluate the feasibility of a PS-based vaccine for the delivery of the 
Lassa virus antigen, Glycoprotein 1 (LASV-GP1). Although in terms of quantity we observed 
no differences between the PS-loaded protein and the soluble form, our data displayed an 
enhancement in the quality of the antibodies elicited, which had an increased binding to 
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LASV-GP1 when displayed in its native conformation and displayed a broader epitope 
targeting. 
Finally, we demonstrated that, besides classical antigen-presenting cells, non-hematopoietic 
stromal cells also scavenge foreign antigens.  We showed that lymph node lymphatic 
endothelial cell (LECs) internalize and process exogenous proteins in inflammatory and non-
inflammatory conditions in vivo. Although with our approach we could not detect the 
implications of LECs presentation in the functional outcome of immune responses, we 
hypothesize that the elucidation of the roles of LECs on the tuning of immunity will bring 
novel modes of immunomodulation of vaccines. 
In summary, this thesis describes a comprehensive study of the adaptive immune responses 
generated after intradermal delivery of particulate-based vaccines. Furthermore, this thesis 
accomplishes the aims to establish new insights and immediately applicable guidelines for 
vaccine design. 
 
Keywords:  
Nanoparticles, polymersomes, antibodies, Lassa, lymph node, vaccine, quality, CD8 T cell, 
CD4 T cell, B cell, dendritic cell 
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RÉSUMÉ 
 
Les vaccins ont diminué la prépondérance et les épidémies de maladies infectieuses en 
induisant une protection contre les pathogènes, réduisant ainsi la morbidité et mortalité. Le 
succès des méthodes standard de vaccination, telles que les immunisations avec des 
vecteurs vivant atténués, dépend de la reconnaissance des composants pathogéniques par 
le système immunitaire, qui à son tour influence la réponse immunitaire adaptative afin 
d’éradiquer le pathogène. Néanmoins, les soucis de sécurité associés avec les vecteurs 
vivant atténués n’ont pas permis une application large de ces vaccins. Par conséquent, les 
vaccins sous-unités, composés de composants microbiaux et protéiques, sont apparus pour 
induire une immunité protectrice, offrant ainsi un mode d’immunisation plus simplifié, sûr et 
standardisé. 
Les composants uniques d’un vaccin, tels que les protéines et les adjuvants, ne sont pas 
aussi immunogéniques que les pathogènes entiers, donc il y a un réel besoin de nouvelles 
stratégies pour augmenter leur immunogénicité. Les nanovecteurs (< 1000 nm) sont un 
moyen prometteur pour le transport de protéines et d’adjuvants : ils peuvent augmenter les 
réponses immunitaires en empêchant la dégradation rapide des protéines, promouvant la 
rétention des antigènes dans les organes lymphoides, et permettant le ciblage des cellules 
dendritiques (DC) dans les ganglions lymphatiques. Au vu de l’efficacité des vaccinations 
basées sur les nanovecteurs, notre laboratoire a développé deux plateformes basées sur le 
poly(éthylène glycol) (PEG) et le poly(propylène sulfide) (PPS) : les nanoparticules (NPs) et 
les polymersomes (PSs) diffèrent par leur taille, la méthode de cargaison et de le livraison de 
l’antigène. 
Dans cette thèse, nous avons évalué l’impact de la livraison antigénique par les 
nanovecteurs sur la magnitude et la qualité des réponses immunitaires cellulaires et 
humorales. Nous avons d’abord étudié comment les NPs modulent la réponse CD8+ T 
cellulaire face à un épitope MHCI viral et avons démontré que le chargement des NPs peut 
augmenter drastiquement la magnitude de la réponse cellulaire. Ensuite, nous avons 
demandé quelle est la différence dans la réponse cellulaire face à un vaccin basé sur les 
DCs, qui est un type d’immunisation standard. Nous avons montré que la qualité de la 
réponse CD8+ T mémoire était changée de manière drastique, les NPs promouvant des 
cellules T CD8+ avec un phénotype effecteur caractérisé par une fort expression de KLRG-1 
et un faible marquage de CD43, CD27 et CD62L. En contraste, la vaccination DC a promu 
un phénotype type mémoire centrale chez les cellules T CD8+. 
Les travaux récents de notre laboratoire ont montré que les réponses T induites par les NPs 
et PSs diffèrent de manière significative selon le vecteur, avec les NPs qui augmentent les 
réponses cytotoxiques et les PSs qui augmentent les réponses T CD4+. Ici, nous avons 
démontré que l’activation préférentielle des cellules T est une conséquence d’un trafic 
intracellulaire distinct et d’une biodistribution de l’antigène à travers les organes différente, 
qui est promue par les propriétés du nanovecteur. De plus, nous avons observé que les PSs 
sont de meilleurs activateurs des cellules T CD4+ et inducteurs plus efficaces des cellules T 
folliculaires (Tfh), ce qui s’est traduit par une augmentation des centres germinaux de 
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cellules B, qui sont bénéfiques pour le développement de vaccins basés sur les réponses 
humorales. Sur la base de ces résultats, nous avons décidé d’évaluer la faisabilité d’un 
vaccin PS pour la livraison de l’antigène du virus Lassa, glycoprotéine 1 (LASV-GP1). Bien 
qu’en terme de quantité nous avons observé aucune différence entre la protéine libre et la 
protéine sur les PSs, nos résultats suggèrent une augmentation de la qualité des anticorps 
induits par les PSs : les anticorps se liaient davantage à LASV-GP1 dans sa conformation 
native et ciblaient un panel plus large d’épitopes. 
A la fin, nous avons aussi démontré que, en plus des cellules présentatrices d’antigène 
classiques, les cellules stromales hématopoiétiques pouvaient aussi pourchasser les 
antigènes étrangers. Nous avons montré que les cellules endothéliales lymphatiques (LECs) 
dans les ganglions pouvaient internaliser et digérer des protéines exogènes dans des 
conditions inflammatoires et homéostatiques in vivo. Même si nous n’avons pas détecté 
l’implication des LECs dans le résultat fonctionnel des réponses immunitaires, nous posons 
l’hypothèse que l’élucidation des rôles joués par les LECs dans la modulation de l’immunité 
forgera de nouvelles méthodes d’immunomodulation par les vaccins. 
En résumé, cette thèse décrit une étude compréhensive des réponses immunitaires 
adaptatives générées après la livraison intradermale de vaccins basés sur des 
nanovecteurs. De plus, cette thèse accomplit le but d’établir de nouvelles informations et 
lignes directrices pour le design de nouveaux vaccins. 
 
Mots-clefs 
Nanoparticule, polymersome, anticorps, Lassa, ganglion lymphatique, vaccin, qualité, cellule 
T CD4+, cellule T CD8+, cellule B, cellule dendritique 
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Chapter 1 INTRODUCTION 
Motivation, background and outline of the 
thesis 
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1.1 MOTIVATION 
 The need for subunit vaccines 
It is indisputable that vaccines have diminished the burden of infectious diseases by reducing 
disability and mortality 1. Vaccination has proven to be a safe and cost-effective mean of 
prevention of illness that has brought enormous economic benefits, especially in the 
developing world 2,3. 
The goal of vaccines is to program the immune system to rapidly respond and protect in case 
of pathogen exposure. To date, the most successful vaccines are live attenuated viruses, 
which were developed empirically in the nineteenth-century and consist of weakened 
pathogens that simulate natural infection without promoting disease. The success of this type 
of vaccine is inherent to the pathogens used, since they encode for a broad set of 
immunostimulatory molecules that efficiently trigger the immune response.  However, the 
great efficacy of these approaches comes with a safety cost, as some of these vectors regain 
virulence and convert into a pathogenic form 3–6. Furthermore, for chronic diseases such as 
infection with human immunodeficiency virus (HIV), mimicking the natural infection is not 
enough to promote protection, and thus new strategies of vaccination are needed 7.  
There has been enormous progress in the understanding of how vaccines and the immune 
system work, which has made possible the development of rationally designed vaccines.  For 
instance, we know that innate immunity has evolved to recognize and respond to pathogens, 
and moreover, that it has the ability to tune the adaptive immune system in order to react in a 
way that eradicate the infection 8,9. This is achieved by pattern recognition of molecules 
associated with microbes (pathogen-associated molecular patterns, PAMPs) through 
different receptors (pattern recognition receptors, PRRs), whose activation will determine the 
magnitude and quality of the immune response. Thus, innate immune cells, such as antigen 
presenting cells (APCs) not only modified the adaptive immune system through antigen 
presentation, but also delivering key signals for the differentiation of lymphocytes into distinct 
subsets (Fig1-1). In fact, live attenuated vaccines such as the yellow fever vaccine (YF-17D) 
and smallpox vaccine activate various PRRs that synergistically activate T cells and B cells 
to promote long-lasting immunity 10,11  
Understanding which components of existing vaccines enable a potent activation of the 
immune system made it now possible to isolate antigenic parts from a pathogen, thereby 
avoiding the inclusion of virulent factors that promote disease. Subunit vaccines made use of 
these antigenic components and thus offer a much safer, controlled and targeted mode of 
immunization 12,13. Yet, the immunity induced by single pathogen components is currently not 
comparable to that offered by live attenuated vaccines. Subunit vaccines are usually 
comprised of small molecules that lack enough immunogenicity and that are rapidly cleared 
from the circulation, and thus their changes to encounters immune cells are limited. 
Consequently, parameters such as the route of administration, method of delivery, and 
selection of immunostimulatory compounds (adjuvants) must all be specifically tuned to 
enhance not only the magnitude, but also the quality of the immune response to novel 
subunit vaccine candidates. 
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Figure 1–1 Types of helper responses promoted by pattern recognition receptors (PRRs) in 
innate immune cells. Antigen presenting cells, such as Dendritic cells (DCs) integrate signals from 
diverse pathogens through PRRs, secreting key signals that influence the type of T helper (Th) cell 
induced. Image adapted from 14.  
 Targeting Emerging diseases: Lassa fever 
The Lassa virus (LASV) belongs to the Arenaviridae family, a rodent-borne group of viruses 
that are causative agents of severe hemorrhagic fevers in regions of Africa and in South 
America. Structurally, arenaviruses have a bisegmented negative single-stranded RNA 
genome, which encode for four proteins: the Glycoprotein precursor (GPC), the 
nucleoprotein (NP), the RNA polymerase (L) and the Matrix protein (Z). The genome is 
enclosed in a lipid membrane bearing trimers of the glycosylated proteins, GP1 and GP2, 
which interact closely with each other forming spikes that adorn the surface of the virus. GP1 
and GP2 are derived from the GPC precursor: GP1 is responsible for interacting with the 
receptor for cell infection, whereas the GP2 is the fusion-active transmembrane protein 
(Fig1-2) 15–17. 
Lassa hemorrhagic fever is caused by the LASV, which is endemic in countries of West 
Africa, mainly Sierra Leona, Guinea and Liberia. Currently, the only treatment available is an 
antiviral drug, Ribavirin, although it is only effective when delivered early in the course of the 
disease 18.  Approximately 5,000-10,000 people die yearly from Lassa fever 19. A study from 
2014 indicated that the mortality rate of patients diagnosed with the disease could reach 
values as high as 60%. This mortality rate was observed even after Ribavirin treatment, 
which suggests that current therapeutic methods for LASV are inefficient, and underscores 
the need for an effective vaccine or treatment 20.  
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Figure 1–2 Virion structure (A) and genome organization (B) of Arenaviruses (Image courtesy of 
Clara Galan Navarro) 

Vaccination with live attenuated pathogens in the zones where LASV is endemic is very 
improbable, mainly for safety concerns, since a large proportion of the population is 
immunocompromised due to the incidence of Malaria, HIV/AIDS and Tuberculosis 18.  
Despite this, most of the current research towards a LASV vaccine involve live pathogens as 
antigen carriers 21–23, and most of the safer approaches evaluated such as virus-like particles 
or DNA vaccines lack the immunogenicity needed for a protective immunity24–26.  Thus, there 
is an opportunity and a need to engineer a safe and effective subunit vaccine against LASV.   
In order to understand the best strategy to develop a subunit vaccine against Lassa is 
important to consider the immune response that allows for the control of Lassa virus in 
subjects that survive the disease.  
The recovery of Lassa patients and experimental animals has been mainly associated to 
CD8 T cell immunity, since antibody levels in serum during the onset of the disease do not 
correlate with LASV protection. In fact, high antibody titers reflect the uncontrolled levels of 
viremia, and represent a bad prognosis for infected patients.  Moreover, studies from 
monkeys that recover from the infection demonstrated high levels of activated cytotoxic T 
lymphocytes (CTLs), compared to the monkeys that died from the disease 27 .  
However, there is evidence that after the virus is cleared, neutralizing antibodies (nAbs) 
against the Lassa glycoprotein can develop, and more importantly, these antibodies can be 
protective. These antibodies can remain detectable in the blood of convalescent patients, 
and might prevent from a future infection. Furthermore, some reports indicate that if passive 
immunization with serum of convalescent patients or animals occurs early during the 
infection, it can prevent death 28,29   
All together, this data suggests that both arms of the immune system (i.e., cellular and 
humoral) are able to promote protection against LASV, although at different times, with CD8 
T cells being important for controlling the disease, and antibodies preventing from acquiring a 
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second infection.  Thus, a novel subunit vaccine might explore inducing both types of 
immunity for the development of a novel LASV vaccine candidate.   
1.2 ENHANCING THE EFFICACY OF SUBUNIT VACCINES 
 Lymph node targeting of subunit vaccines to dendritic cells  
The first step during an immune response is the antigen uptake by antigen presenting cells 
(APCs), leading to its presentation to cognate T cells. Macrophages, B cells and dendritic 
cells (DCs) are recognized as classical APCs, although DCs are unique in that they have the 
capacity to efficiently present endogenous and exogenous antigen in the context of MHCI 
and MHCII, thus playing a crucial role in mounting both CD8 and CD4 T cell responses 30–33.  
Therefore, targeting subunits vaccines to DCs is an attractive strategy to enhance the 
potency of vaccines.  
DCs are found in high numbers in secondary lymphoid organs (SLO) such as lymph nodes, 
where they are strategically located in order to maximize their encounter with lymphocytes 
for the initiation of the immune response 31,34. Thus, the main events of adaptive immunity 
such as T cell differentiation and B cell class switching and maturation occur in lymph nodes 
35.  A relatively easy method to target subunit vaccines to lymph nodes is by administering 
subunit vaccines through the intradermal route. In the skin, lymphatic capillaries take up 
macromolecules from the periphery, which reach afferent lymphatic vessels that drain to 
local lymph nodes 35–37.  In fact, many infections occur through this route, so the intradermal 
route of administration of subunit vaccines closely resembles the natural route of such 
infections. 
Subunit vaccines may be transported to lymph nodes by migratory DCs, or may also traffic in 
a cell independent manner. Within the lymph nodes, subunit components are taken up by 
diverse DCs with specialized functions. For example, CD8+ DCs are recognized by their 
capacity to process exogenous antigens and present them to CD8 T cells, a process known 
as crosspresentation, which is crucial for defeating intracellular viral infections. Another 
important subset of DCs is the CD11b+ DCs, which instead are known to promote MHCII 
presentation, thus enhancing CD4 responses 30,31,38,39.   As such, immune responses cannot 
only be enhanced by broadly targeting DCs, but can also be tuned to a specific type of 
immunity by targeting DC subsets using rationally designed antigen delivery systems. 
 Antigen delivery in Nanoparticulate platforms 
Nanoparticulate carriers (<1000nm) have been widely used in the last few decades to 
enhance the immunogenicity of antigens, such as peptide and proteins (Table1). 
Nanoparticle platforms have a similar size range to that of pathogens, and are readily taken 
up by innate immune cells such as DCs, since these cells preferentially internalize particulate 
shapes. Further, nanoparticle carriers protect the antigen from early degradation, and allow 
for controlled release of antigen over time. This, in turn, promotes antigen retention in 
lymphoid organs, enhancing the chances of DCs to uptake protein or peptides and mount an 
immune response 37,40–42.  
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LIPOSOMES 
Phospholipid vesicles that allow for 
the encapsulation of antigen within 
the particle.  Introduction of lipids 
with chemical functionalities allow 
also for the incorporation of antigens 
in the liposome surface.  
Vedantra Pharmaceuticals:  Human 
Papilloma virus 
ISCOMs 
Cage-like colloidal carriers in which 
antigen is incorporated. Composed 
of cholesterol, phospholipids and an 
in built adjuvant, Quil A (derived from 
Quillaia Saponin)  
CSL Behring: Human Papilloma virus, 
Hepatitis C, Influenza 
VIRUS-LIKE 
PARTICLES 
(VLPs) 
VLPs are form from the self-
assembly of viral structural proteins, 
derived for example from Envelope 
or Capsid. Represent a safer mode 
of vector since they lack the genetic 
component of the virus, and thus are 
not replicative.  VLPs offer the 
advantage to present proteins on the 
VLP surface in their native 
conformation. 
Merck: Human papilloma virus 
(Gardasil ®) 
GSK: Human papilloma virus (Cervarix 
®), Hepatitis B virus (Engerix ®) 
Crucell: Ebola virus, Influenza, Polio, 
HIV 
Pevion Biotech: HIV, Influenza, 
Malaria, Herpes Simplex Virus, 
Respiratory syncytial virus 
Novovax: Respiratory syncytial virus, 
Influenza, Ebola virus 
SYNTHETIC 
PARTICLES 
Colloidal particles usually composed 
of preformed polymers or by 
polymerization of monomers.   
Synthetic particles allow for antigen 
incorporation within the particle, or 
on the surface though diverse 
methods of chemical conjugation.  
Selecta Biosciences: Nicotine 
addiction, Malaria, type I diabetes 
Liquidia Technologies: Pneumoniae, 
Influenza 
Vical: Herpex virus 2,Cytomegalovirus 
 
Table 1 Main nanoparticle based delivery systems in the clinic and preclinical development  
(Information from 37,50,51) 
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In addition, the design of the nanocarrier also has a drastic impact on the outcome of 
adaptive immunity.  For instance, when particulates are delivered intradermally, the size of 
the carrier has a marked impact on the uptake by lymphatic capillaries, which in turn affects 
lymph node targeting. It is generally considered that particles between 10-50nm have an 
optimal size for entering the lymphatic system instead of the blood, while larger solid 
particles experience more resistance to lymphatic uptake, and are retained at the injection 
site for longer periods of time 35–37,43. Furthermore, particle size will also determine the 
mechanism of cellular internalization, namely phagocytosis, macropinocytosis or receptor 
mediated endocytosis, which in turn impacts the type of immune response elicited 42. 
The mode of antigen loading offers also another way to manipulate immune responses. 
Antigen may be encapsulated inside the carrier, or loaded on their surface via degradable or 
non-degradable covalent bonds 44–48. For instance, surface coupling is believed to be 
beneficial for B cell responses, as it allows the recognition of the antigen by the B cell 
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receptor 44.  However, it requires further modification of the antigen, which could disrupt 
immunogenic sites crucial for a protective response. In spite of this, it advantageously allows 
for a more controlled antigen release, since the coupling may be reduction sensitive or acid 
labile, which allows for antigen release in endosomal compartments inside the cell 42,46,47. 
Consequently, a careful selection of the antigen loading technique, particle size, and method 
of antigen release are factors to take into consideration for the design of particulate subunit 
vaccines.  
 Addition of TLR ligands as adjuvants 
Activation of T cells not only requires antigen presentation through MHC molecules. In fact, T 
cells must encounter an APC that displays multiple signals: Signal 1 is the interaction 
between the cognate TCR receptor with the APC via peptides-MHC complexes, signal 2 is 
the engagement of costimulatory receptors on T cells by their ligands presented on APCs, 
and signal 3 is the inflammatory stimulus that instructs T cell behavior 13,14,30,33.  
All three signals are strongly modulated by the addition of adjuvants that augment and tune 
the adaptive immune response. In fact, adjuvants are a crucial components of subunit 
vaccines, as their activity will direct the immune response towards particular phenotypes, 
which is highly important since diverse pathogens require different types of immunity 7,37,52–54.  
Toll like receptors (TLRs) ligands are compounds that stimulate TLRs, a family of PRRs that 
sense a broad range of conserved patterns found in pathogens. The stimulation of TLRs 
initiates a signaling cascade of events that results in a variety of cell responses, including the 
secretion of pro-inflammatory cytokines that orchestrate adaptive immunity 8,9,55,56.   
Among various TLRs, TLR3, TLR-4, TLR-7/8 and TLR-9 ligands are well-documented and 
recognized modulators of vaccine efficacy. These ligands are known to promote Th1 biased 
immune responses, characterized by the presence of cytokines such as IFN and 
TNF, which are important for the elimination of viruses and intracellular pathogens (Fig1-1)  
55.  
TLR3 ligands are double stranded RNA that is produced during the replication of viruses 
within cells, and also during cell damage. Poly I:C are synthetic RNAs that resemble TLR3 
ligands, and are potent inducers of IL-12 and type I interferons. Administration of TLR3 
ligands in vaccine formulations promotes a strong activation of NK cells, as wells as potent 
antigen crosspresentation, thus enhancing the generation of cytotoxic CD8 T cells.  
However, Poly I:C ligands are in general not well tolerated and might promote toxic side 
effects 55   
The ligands for TLR-4 are bacterial lipopolysaccharides (LPS) that display potent 
immunostimulatory properties. Monophosphoryl lipid A (MPLA) is a derivative of LPS, which 
has a much safer profile while still retaining its immunomodulatory properties 55,57.  MPLA is 
known to be very effective at promoting both CD8 and CD4 T cell responses, as well as 
inducing long lasting humoral responses 58–61. Currently, MPLA is used as the adjuvant in two 
vaccines approved for their use against human papilloma virus (HPV) and HBV (Cervarix® 
and Fendrix®).  MPLA is also studied for use in clinical vaccine candidates against malaria 
and tuberculosis 2,7.  
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TLR-9 ligands are synthetic oligonucleotides containing CpG motifs, which mimic bacterial 
DNA. CpG-B (CpG ODN) is perhaps the most used and best-characterized type of TLR-9 
agonist 55,57. When delivered in combination with soluble antigens or added to standard 
vaccine formulations, it enhances the magnitude and the quality of immune responses, and 
promotes long lasting cellular and humoral responses 58,62–65. CpG-B acts on a broad range 
APCs, improving antigen uptake and presentation as well as cytokine secretion (IL6, TNF-, 
IFN- and IL-12) 57,66–69.  Preclinical studies also demonstrate that this adjuvant has a good 
safety profile, thus marking CpG-B as a very promising immunomodulatory agent 57,69.  
TLR-7 and TLR-8 (TLR-7/8) are structurally similar, and play important roles in the response 
to viral infections. Both receptors recognize single stranded RNA as well as synthetic base 
analogs 70,71.  In humans, TLR-7/8 are expressed in almost all types of DCs, which make 
them attractive for their implementation in vaccine formulations 72.  Synthetic agonists of 
TLR-7/8 such as imidazoquinolines are known for being strong potentiators of antiviral and 
antitumoral T cell responses 60,73–76 .  There are two synthetic activators of TLR-7 and 
TLR7/8, Imiquimod and Resiquimod, which are approved for topical in use in humans against 
viral infections and skin cancers72. 
 Blockade of tolerogenic signals 
In addition to typical APC-mediated routes of antigen presentation, “atypical” modes of 
antigen presentation by non-hematopoietic cells have recently been described. In LNs, there 
are four populations described on the basis of CD31 and Podoplanin (gp38) expression. The 
subclasses are fibroblastic reticular cells (FRCs), lymphatic endothelial cells (LECs), blood 
endothelial cells (BECs) and a group of double negative cells (DN, CD31-gp38-) that groups 
perycites and a subset of undefined cells 31,33.  
These stromal cell subsets have been demonstrated to upregulate MHCI and MHCII upon 
exposure to an inflammatory stimuli 77, and are also able to present antigen to T cells. 
However, the consequences of antigen presentation by these subsets have mainly 
tolerogenic implications. For this reason, stromal cells are currently acknowledged as one of 
the main components of peripheral tolerance, as their constant MHCI and MHCII 
presentation promotes T cell deletion and maintenance of regulatory T cells 78–84.  
A potential benefit for enhancing the efficacy of subunit vaccines is to reduce tolerogenic 
signals that might dampen immunogenic responses. In the field of cancer immunology this 
concept has been widely studied.  For example, co-administering cancer vaccines with 
blocking antibodies targeted against inhibitory receptors expressed on T cells enhances the 
anti-tumorigenic immune responses85.  Therefore, strategies to inhibit or reduce tolerogenic 
signals derived from stromal cells might serve as a novel stroma-targeting immunotherapy, in 
order to increase the effectiveness of subunit vaccines.  This is a strategy that has been 
previously suggested, but that is mostly unexplored, although it has the potential to bring 
novel opportunities to the field of vaccinology. 
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1.3 AIMS OF THE THESIS 
Our group has recently developed two nanocarriers based on Polyethylene glycol (PEG) and 
propylene sulfide (PPS), called Nanoparticles (NPs) and Polymersomes (PSs), which differ in 
size, method of antigen loading and method of antigen release (Fig1-3).   
In this thesis, we sought to characterize the immune response to the types of particles in 
order to outline which platform would be beneficial for promoting a cellular response or a 
humoral response, since both types of immunity are potentially beneficial for a vaccine 
against LASV. For this purpose, we took advantage of two well-studied antigens, the 
Lymphochoriomeningitis virus (LCMV) MHCI restricted peptide GP33-41 and the protein 
Chicken Egg Ovalbumin (OVA), in order to better characterize how the types of carriers 
modulate the magnitude and quality of the adaptive immune response.  
We thus aimed at 1) establishing a particle-based vaccine able to promote long lasting 
memory CD8 T cell responses, 2) evaluating which particulate system promotes a higher 
magnitude and better quality humoral response and 3) understanding whether modulating 
the stroma could lead to improvements in the outcome of adaptive immune responses to 
vaccines employing nanoparticles.  Finally, we aimed to apply these findings to develop a 
subunit vaccine against LASV.  
 
 
Figure 1–3 Nanoparticle-based carriers based on PEG and PPS. Left, nanoparticles, right, 
polymersomes. Image adapted from Stano et al 86.  

1.4 OUTILINE OF THE THESIS 
In Chapter 2, we use the nanoparticle (NP) platform for the delivery of the MHCI peptide, 
GP33-41. We made use of the NPs since this carrier has proven to be very efficient in 
promoting antigen specific CD8 T cell responses, able to protect against an influenza 
challenge, as well to significantly enhance tumor regression and host survival in various 
murine tumor models 63,64,87.  Initially, we described the efficacy of NPs to stimulate CD8 T 
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cell responses upon intradermal delivery. We demonstrated that coupling of peptide via a 
reducible bond significantly enhances the number of antigen specific CD8 T cells over free 
peptide formulation. Furthermore, we demonstrated that the presentation of MHCI peptides 
in NPs promotes a functional population of memory CD8 T cells. Finally, we showed that 
nanoparticle loading has a strong impact on the quality of the immune response, skewing the 
memory CD8 T cells to an effector-like memory phenotype. 
In Chapter 3, we wanted to select the platform ideal for the development of protective 
humoral-based responses. Thus, we compared the ability of NPs and PSs to induce good 
quality and long lasting CD4 T cell helper cells and antibody responses to the model antigen 
OVA. Since previous experiments described an enhanced capacity of PSs to promote CD4 T 
cell responses 86, we initially explored the mechanisms behind these observations. Our 
results demonstrate that the PSs promoted a distinct intracellular trafficking and a differential 
organ biodistribution of the antigen, which had significant consequences on the activation of 
CD4 T cells. Furthermore, we found remarkable differences in the quality of cellular and 
humoral responses, with PSs enhancing follicular T helper cells over the NPs platform, which 
translated in an increase in germinal center B cells and plasma cells.  
In Chapter 4, we apply our findings from Chapter 3 to develop a subunit vaccine candidate 
against LASV, employing PSs as particle vectors owed to their capacity to promote cellular T 
helper responses. We demonstrated the feasibility of producing the Lassa glycoprotein 1 
(LASGP1), which is hypothesized to be the target of protective antibodies. Furthermore, we 
showed that LASVGP1 can be encapsulated into PSs in a reproducible manner. By 
employing a whole-virus ELISA and a peptide microarray, we demonstrated that 
encapsulation of LASVGP1 protein within the PSs changes the profile of the epitopes that 
were recognized by serum antibodies, indicating a qualitatively enhancement of the humoral 
response.  
In Chapter 5, we demonstrated that lymphatic endothelial cells selectively scavenge and 
process foreign exogenous antigen in inflammatory and non-inflammatory conditions. We 
also explored the feasibility to intervene with signals from the LEC stromal cell subset to 
modulate antigen specific CD8 T cell responses. We show that the administration of a 
monoclonal antibody to block the signaling through VEGFR3, one of the main receptors 
responsible for proliferation of LECs under inflammatory conditions, has no discernable effect 
on the magnitude or the quality of the elicited CD8 T cell response.  
Finally, I Chapter 6 we summarize our findings, discuss about the implications of our results 
and present the future prospects of our studies.  
 
  
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2.1 ABSTRACT 
 
The induction of protective T cell mediated immunity is one of the major goals for therapeutic 
and prophylactic vaccines. Herein, we made use of PEG-PPS nanoparticles (NPs) 
developed in our group for the delivery of a synthetic peptide representing the MHCI 
restricted epitope GP33-41 derived from the Lymphochoriomeningitis virus (LCMV).  We 
demonstrate that a prime boost homologous immunization promotes a significant increase in 
the magnitude of CD8 T cell responses when comparing to an unformulated peptide and to a 
dendritic cell-based vaccine. We show that NPs promoted a robust pool of memory CD8 T 
cells with an effector-like phenotype, characterized by a high expression of killer cell lectin-
like receptor G1 (KLRG1) and low expression of CD43, CD27, CD127 and CD62L. The NP 
generated memory CD8 T cells exhibited a similar polyfunctional activity in vivo compared to 
those generated via a control dendritic cell vaccine, which displayed a central-memory like 
phenotype. These studies demonstrate the feasibility to use NPs for inducing robust and long 
lasting CD8 T cell responses, and emphasize the importance of the antigen carrier for tuning 
the quality and the magnitude of the immune response.  
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2.2 INTRODUCTION 
A major goal in vaccinology is to promote protective immunity mediated by CD8 T cells. T 
cell immunity has been associated with pathogen control and clearance during acute viral 
infections, such as Epstein-Barr virus (EBV) and Influenza 1,2 . Moreover, in the case of 
established diseases such as human immunodeficiency virus infections (HIV), Hepatitis B 
(HBV) or cancer, induction of CD8 T cells is necessary for the success of the vaccine 3,4.  
In therapeutic and prophylactic vaccines, the magnitude of cellular immunity elicited has 
been positively correlated with viral clearance and resolution of the infection 5.  Nevertheless, 
considering uniquely CD8 T cell frequency does not necessarily reflect the functionality of the 
cellular immune response, as illustrated during chronic infections, where CD8 T cells are 
present but are dysfunctional and unresponsive 6. Therefore, to better predict the efficacy of 
vaccines, phenotypic markers have been described as qualitative correlates of protection.  
However, there have been discrepancies in the literature about which phenotype is beneficial 
for a protective immune response. 
Earlier studies have described two types of memory T cells, T central memory (Tcm) and T 
effector memory (Tem). This nomenclature was given depending on the ability of the cells to 
migrate to lymphoid organs founded on the expression of chemokine receptors such as 
CCR7 and CD62L.  Thus, Tcm cells (CD62L+ CCR7+) mainly have the ability to localize in 
lymphoid organs, while Tem (CD62L- CCR7-) cells tend to patrol the periphery. Tcm cells 
also display a higher proliferative potential compared to Tem, while Tem are characterized by 
a rapid effector function7. Joshi et al extended this phenotype to mouse by describing the 
quality of the immune response based on the expression of killer cell lectin-like receptor G1 
(KLRG1) and the interleukin-7 (IL-7) receptor alpha chain (CD127) 8. Starting from the 
observation that KLRG1+ cells undergo apoptosis and are present at very low frequencies 
during the memory phase, they proposed that the quality of the CD8 responses could be 
predicted early during the CD8 response by defining CD127+ KLRG1- as memory precursors 
effector cells (MPECs), and CD127-KLRG1+ as short lived effector cells (SLECs).  
Therefore, it may appear that for an efficacious response, vaccines that elicit T cells with a 
Tcm and MPEC phenotype are preferable to those that generate a bias towards Tem, 
suggesting that KLRG1+ CD62L- memory cells are not involved in mediating long-term 
protection against pathogens. However, the data on the protective capacity of Tem/SLECs 
and Tcm/MPECs subsets is contradictory, and there are various reports suggesting that 
KLRG-1 and CD62L have limited value as biomarkers associating with long-term protection . 
For instance, Tem cells promoted equally or even better protection than Tcm cells in a model 
of Malaria and Sendai virus infection 9,10 . Moreover, in the context of cancer, CD62L- 
KLRG1+ CD8 T cells were the subset that correlated the best with therapeutic vaccine 
efficacy against established subcutaneous tumors 11 .   
Recently Hikono et al. reported a new characterization of memory CD8 T cells responses 
based on the expression of the activation markers CD43 and CD27. In this classification, 
CD43+/-CD27+ cells resemble Tcm in their capacity to proliferate, but it was the CD43-
CD27+ subset that was responsible for controlling a Sendai virus infection in the lungs 12. 
However, the accuracy of this classification has been already questioned by a report by 
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Olson et al 13. Although they found the same subsets as reported by Hikono, in his hands the 
effector-like memory population (CD43-CD27-) was maintained for a long time after 
immunization, and by means of a strong cytolitic activity, displayed much higher protective 
capacity than the other subsets.   
Our group has developed an antigen carrier based on propylene sulfide nanoparticles (NPs). 
The use of this system to deliver antigens has proven to be very efficient in promoting 
antigen specific CD8 T cell responses, able to protect against an influenza challenge, as well 
to significantly enhance tumor regression and host survival in various murine tumor models 
14–16. Considering the disagreements of the literature in defining a clear correlate of 
protection, we wanted to deeply characterize the phenotype of the cellular response elicited 
upon NP immunization in order to establish in our system how the properties of NP-induced 
CD8 T cells are associated to the quality of the immune response.  
We examined the CD8 T cell responses to the MHCI restricted epitope GP33-41 derived from 
the Lymphochoriomeningitis virus (LCMV) upon delivery in NPs.  First, we demonstrate the 
superiority of this platform over a soluble peptide in enhancing the magnitude of CD8 T cell 
responses. We showed that NP vaccination also promotes the survival of a robust population 
of CD8 memory T cells with an effector-like phenotype, characterized by a high expression of 
KLRG-1, and lack of CD62L, CD43 and CD27 in a dose independent manner. In vivo, both 
DC and NP memory CD8 T cells displayed similar cytokine secretion in response to a viral 
challenge, although they varied in their proliferative capacity. Our future studies will examine 
the protection capacity of the effector-like skewed phenotype induced after the NP 
immunization in models of acute and chronic viral diseases, as well as the efficacy of these 
CD8 T cells in therapeutic cancer vaccines.  
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2.3 MATERIALS AND METHODS 
Animals  
C57BL/6 female mice, age between 8-12 weeks, were purchased from Harlan (France). 
Thy1.1+ P14 mice, which encode for a T cell receptor that is specific for the LCMV MCHI 
epitope GP33-41, were obtained from the group of Pedro Romero at CHUV. All animal 
experiments were performed under the approval from the Veterinary Authority of the Canton 
of Vaud (Switzerland) according to Swiss Law.   
Infections 
The LCMV 53b Armstrong virus was obtained from the group of Dietmar Zehn at the CHUV. 
Mice were infected intraperitoneally (i.p.) with 2.5 x105 p.f.u., which initiates a systemic 
infection that is usually cleared during the first week post infection.  
Peptide activation 
GP33-41 (KAVYNFATC) peptide was purchased from Thermo Scientific with a purity of >95%.  
Peptides were activated by adding a 2-pyridylthiol group to the cysteine residue 17. Peptide 
purity and activation was confirmed by analytical HPLC/MS.  
Nanoparticle preparation 
All chemical reagents were reagent grade and purchased from Sigma-Aldrich unless 
otherwise stated. Polypropylene sulfide nanoparticle (NP) synthesis was detailed previously 
18. Briefly, Pluronic F127 (surfactant, OH-PEG) and Propylene sulfide (PPS) were mixed in 
10 mL of H2O. The reaction vessel was evacuated and re-equilibrated with inert gas, and 
incubated for 30 min to form nanoemulsions of Pluronic encapsulating the hydrophobic PPS 
monomers. Next, 14.8 mg of 4-Arm initiator (synthesized in house), previously activated in 
0.5 M NaOCH3 (solution in MeOH), were added to the Pluronic-PPS emulsion and mixed for 
15 min, after which, the addition of 60 µL of 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU)  
begins the polymerization of the PPS core of the emulsions. This reaction is allowed to 
proceed for 16 hrs under an inert gas atmosphere, and then crosslinking of the polymers is 
accomplished by subsequently mixing the reaction under ambient air for 2 hrs . Completed 
NPs were purified by dialysis against MQ H2O for 36 hrs at room temperature, and finally 
filtered through a 0.22 µm membrane (Millipore Corporation). For quantification of the 
amount of thiols in the NPs, we used a modified Ellman’s assay, using as a standard 
thiomalic acid.  
Peptide coupling was achieved by mixing NPs with activated peptide for 16 hrs at room 
temperature. The reaction was monitored by measuring the absorbance at 340 nm, which 
represents the release of pyridyl thione from the peptide as the peptide reacts with free thiols 
on the NPs. NPs-peptide conjugates were purified from free antigen by size exclusion 
chromatography through a CL-6B Sepharose column equilibrated in physiological saline 
solution (Braun). Fractions containing the antigen were detected by a BCA assay (Thermo 
Scientific).  
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Before and after the coupling, the size of NPs was determined by dynamic light scattering 
with a Nano Zs Zetasizer (Malvern Instruments). The diameter of NPs varied between 35 
nm-40 nm. 
Generation of bone marrow derived DCs  (BMDCs) 
Bone marrow derived CD11c+ dendritic cells (BMDCs) were generated by adapting the 
protocol described by Lutz et al 19. Briefly, BM cells were cultured for 8-9 days in the 
presence of 20ng/mL of GM-CSF, changing the medium every 3 days.  After this time, 
CD11c+ cells constitute the 70-85% of the non-adherent population.   
The activation of BMDCs in vitro was achieved by stimulating control and LPS treated cells 
with 1 µg/mL of CpG-B (Microsynth) for 16 hrs. Afterwards, the supernatants were collected 
and analyzed by ELISA for the quantification of secreted cytokines.  
Immunizations 
All vaccines were administered intradermally (i.d.) into the 4 limbs. For peptide-loaded NPs 
and free peptide immunization, a total of 2 µg of antigen and 10 µg of the TLR-9 agonist 
CpG-B (Microsynth) were injected per mouse. All NPs and peptide batches were tested for 
endotoxin levels using a TLR activation assay based on HEK-Blue reporter cell lines 
(Invivogen) before immunization. For DC immunizations, BMDCs from day 8-9 were 
activated overnight with 20 ng/mL of LPS. Afterwards, cells were washed with full medium 
and pulsed with 10 µM of peptide for 1 hour at 37°C. To be sure no free peptide remained 
during the immunization, cells were washed extensively (3x) and finally resuspended in 
physiological saline solution at the desired concentration. Shortly before the immunization, 
the cell slurry was mixed with CpG-B. In total, with the exception of the dosing study, each 
mouse received 2x106 cells, together with 10 µg of CpG-B.  
Adoptive transfers and cell sorting 
For adoptive transfers of naive antigen specific CD8 T cells, single cell suspensions were 
prepared from spleens of P14 Thy1.1 mice. CD8 T cells were isolated using the EasySep™ 
Mouse T Cell Isolation Kit (Stemcell Technologies). Immediately after isolation, 2-5x104 cells 
were adoptively transferred i.v. into naïve host mice.  For viral challenge experiments, 
Thy1.1+ P14 CD8 memory T cells were isolated by flow cytometry-assisted cell sorting. 
5x104 cells were adoptively transferred into naïve mice.  
In vivo and in vitro cytotoxic assay 
For in vivo cytotoxic studies, Thy1.1+ P14 cells were adoptively transferred into wild type 
naïve mice, and one day after mice were immunized with NPs or BMDCs loaded with 
peptide, as described above. Four days after the immunization, splenocytes from naïve mice 
(target cells) were divided in two groups: one group was left untreated, while the second 
group was pulsed with 10 µM of GP33-41 for 40 min at 37°C, and then washed two times in 
PBS to remove any free peptide. Following this step, the half that was left untreated was 
stained with 0.4 µM of CFSE (low), while the half that was pulsed with peptide was stained 
with 4 µM of CFSE (high).  Cells were mixed at 1:1 ratio, and a total of 2x107 cells were 
injected i.v. into previously immunized mice. The following day, spleens were harvested and 
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the ratio between the CFSE-low and -high population within each recipient was assessed by 
flow cytometry as a measure of antigen-specific killing.    
ELISAS 
Ready-SET-go! ELISA kits for cytokine detection were purchased from eBioscience and 
used according to the manufacturer’s instructions. 
Preparation of lymph node and spleen suspensions 
For preparing single cell suspensions, lymph nodes were opened with needles and digested 
in DMEM (1.2mM CaCl2, 2% FBS, Pen/Strep) containing collagenase D (500 µg/mL). After 
digestion, lymph node cell suspensions were filtered through a 70µm nylon cell strainer.  For 
spleen, single cell suspensions were prepared by mechanical disruption through a 70 µm 
nylon cell strainer. Splenocytes were further treated with hypotonic ammonium chloride–
potassium bicarbonate buffer to lyse red blood cells.   
Ex vivo restimulation 
Up to 3x106 cells were plated in 96-well plates and cultured in 10%FBS -DMEM medium for 2 
hrs at 37°C in the presence 1 µg/mL of GP33-41. Following this step, 5 µg/mL of Brefeldin A 
were added to the culture and left for 3 additional hrs. For CD107a staining, cells were 
cultured together with the monoclonal antibody against CD107a and with Monensin at 2 
µg/mL for 5 hrs. Finally, cells were washed in PBS prior to staining for flow cytometry.   
Flow cytometry.  
Up to 3x106 cells were plated in 96 well plated and wash once with HBSS before staining 
them with a live/dead fixable dye (Life technologies) to assess cell viability. For surface 
staining, cells were washed once with HBSS supplemented with 0.5% bovine serum albumin 
(BSA, Sigma) (staining buffer) and resuspended in an antibody cocktail using monoclonal 
antibodies from Biolegend and eBiosciences. For intracellular staining, cells were fixed and 
permeabilized with the Foxp3/Transcription Factor Fixation/Permeabilization kit 
(eBiosciences) according to the manufacturer’s instructions.  Cells were stained in 
permeabilization buffer with a cocktail of monoclonal antibodies. After staining, cells were 
resuspended in staining buffer for analysis by flow cytometry.  
Data collection 
Flow cytometry was performed using a CyAnTM ADP (Beckman Coulter) and data were 
analyzed with FlowJo (Tree Star). Because of the small size of the samples, we use the non-
parametric Mann-Whitney U test for statistical comparisons. A P value of less than 0.05 was 
used as an indicator of statistical significance. All data were analyzed using the GraphPad 
Prism 5 Software (GraphPad Software Inc.) 
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2.4 RESULTS 
 Nanoparticles-peptide vaccination augments cytotoxic and polyfunctional CD8 T 
cell responses compared to a soluble antigen 
For peptide loading, we activated the cysteine of the GP33-41 peptide (GP33 hereafter) derived 
from the LCMV with a pyridyl group, as described previously by Hirosue et al. (Fig2-1).  The 
reaction of NPs with thiolate groups with the activated peptide produced nanocarriers with an 
average concentration of 100 µM of GP33 loaded in a reduction-sensitive manner, which is 
advantageous for driving efficient cross-presentation 17. 
 
 
Figure 2–1 Conjugation scheme of nanoparticles to GP33-41.  Thiol bearing nanoparticles were 
incubated with 2-pyridilthiol activated peptides during 16 hours at room temperature. The reaction is 
followed by measuring the absorbance at 340nm corresponding to the release of the protective group 
in the form of pyridine thione 

To determine the potential of NPs to induce CD8 T cells responses, we followed a prime-
boost regime, by immunizing on day 0 and boosting on day 14 intradermally (i.d.) with NP-
GP33 (2µg) and the unformulated peptide, together with 10µg of the TLR9 agonist CpG-B 
(Fig2-2, A). We choose the i.d. administration since this route allows for an easy targeting of 
draining lymph nodes (LNs), enabling the NPs to target various subsets of LN resident DCs  
20. We analyzed the endogenous responses by an ex vivo restimulation with the GP33 peptide 
5 days after the boost, since the peak of the CD8 T cell response to NPs is observed at this 
time 14–16,21. In draining LNs, the NP immunization promoted at least 3-fold higher levels of 
IFN and IFN TNF by-functional cells (6.4% and 1.5%) compared to the unformulated 
peptide (1.9% and 0.5%), while cells secreting IFN, TNF and IL-2 simultaneously were low 
in both immunizations (Fig 2-2, B and C). In the spleen, the NP immunization also promoted 
a significant enhancement of polyfunctional T cells, and furthermore, we found a 3-fold 
higher increase in the frequency of degranulating CD8 T cells, characterized by the 
expression of CD107a, a cell surface marker associated with cytotoxic activity (Fig2-2, B-D). 
Finally, we measured the cytokine secretion in the supernatant of cells from LNs and spleen 
stimulated with the GP33 peptide for 3 days.  Similar to what we observed by flow cytometry, 
we found higher amounts of IFN and TNF in all mice vaccinated with the NPs conjugated 
than those that received the free peptide (Fig2-2, E). All together, this data show that NPs 
promote a quantitative and qualitative enhancement of antigen specific CD8 T cells than 
what is obtained with a soluble antigen.  
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Figure 2–2 Intradermal immunization with nanoparticle-peptide conjugates enhance antigen 
specific CD8 T cell responses to an unformulated peptide. A) Immunization timeline and 
vaccination groups. B) Representative flow cytometry plots for the detection of polyfunctional (left) and 
cytotoxic (right) CD8 T cells. C) Cytokine-secreting CD8 T cells in spleen and draining lymph nodes 
five days after a prime-boost immunization with NP-GP33 and unformulated GP33, together with CpG-B. 
Lymphocytes were restimulated ex vivo with GP33 peptide in the presence of Brefeldin A; cytokine 
expression was assessed by intracellular staining. D) Cytotoxic activity of primed CD8 T cells in the 
splenocytes indicated by the presence of the degranulation marker CD107a. E) Lymph node and 
spleen lymphocytes were cultured for three days in the presence of GP33; IFN and TNF secretion 
were determined by ELISA.  
 
 Nanoparticle-peptide immunization promotes a strong effector phenotype on 
CD8 T cells  
There is little knowledge of the phenotype of the induced memory CD8 T cells upon PPS 
NPs immunization.  Because this is the first time we characterized memory responses using 
this platform, we implemented as a control well-established DC vaccination 22–24 protocol.  
Similar to our platform, DC immunization employs MHCI peptides as antigen and can be 
administered i.d., together with a selected adjuvant.  
DCs were obtained by culturing the bone marrow of naïve mouse for 8 days in the presence 
of GM-CSF, as described elsewhere 19. For immunization, bone marrow derived DCs were 
activated with 20ng of LPS for 12hrs. After this time, DCs expressed high levels of 
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costimulatory molecules such as MHCII, CD40 and CD86 (Fig2-3,A). However, they no 
longer secreted detectable levels of inflammatory cytokines.  Since we used TLR9 as 
adjuvant in this study, we evaluated whether these DCs could be reactivated after addition of 
CpG-B. Indeed, these cells were able to secrete TNF and IL-6 after the addition of 1µg/mL 
of CpG-B, although the levels were lower than untreated BMDCs (Fig 2-3,B).  
 
Figure 2–3 Bone marrow derived dendritic cells (BMDCs) activation in vitro. A) Expression of 
MHCII and CD40 and CD86 costimulatory molecules by BMDCs after 12 hours activation with 
20ng/mL of LPS.  B) Secretion of pro-inflammatory cytokines after 12 hours activation with 20ng/mL of 
LPS is partially restored upon activation with the TLR9 ligand CpG-B. 
 
To facilitate the detection of antigen specific T cells, we transferred Thy1.1+ P14 (2-5x104 
cells), which recognize the LCMV MCHI epitope GP33-41, into wild type mice. One day after 
the transfer, mice were immunized i.d. and boosted at day 14 with NP-GP33 and DCs pulsed 
with 10µM of GP33. All formulations were given together with 10 µg of CpG-B, in order to 
promote the same inflammatory environment in all groups (Fig 2-4, A).  
After immunization, we examined the blood, spleen and LNs at different times and compared 
the frequency of antigen specific cells. In blood, we observed that by day 6 the NP 
vaccination had promoted almost a 6-fold increase in the frequency of antigen specific CD8 T 
cells compared to the DC vaccine (31% vs 5.3%).  By day 14, these CD8 T cells had notably 
contracted in both conditions, but the booster immunization generated a relative increase 
(between day 14 an 19) in the P14 cell frequency of 4.3% and 3.7% for NPs and DCs. This 
secondary response contracted in a less pronounced way, in agreement with published 
reports 25, and left a memory pool that made up 24.1 % (NPs)  and 2.4% (DCs) of the total 
circulating CD8 T cell population by day 90 after the first immunization (Fig2-4, B).  
To study the effect of both treatments on the CD8 T cell phenotype, we performed a 
longitudinal analysis in the blood circulating lymphocytes for the expression of KLRG-1 and 
CD127. To recapitulate, KLRG-1 and CD127 are used to correlate to the formation of 
terminally differentiated cytotoxic T cells, namely short lived effector cells (SLECs, KLRG1+ 
and CD127-), and memory precursors cells (MPECs, CD127+KLRG1-) 8. Between day 6 and 
day 14, we found that CD8 T cells primed by NPs have a phenotype characterized by a 
dominant population of SLEC, and a smaller population of MPEC cells. The DC vaccination 
instead promoted larger frequencies of MPECs, which by day 14 (during the contraction 
phase) represented the 78.6% of the antigen specific cells. The booster immunization two 
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weeks after the priming promoted an increase in the SLECs in both groups, consistent with 
previous reports where a secondary immunization enhanced effector-like phenotype within 
the memory pool 13,25.  By day 90, the populations displayed similar phenotypes as that 
observed after the first contraction, with both groups having as the dominant population the 
KLRG1- CD127+ cells  (36.8% and 46.9% for NP and DCs). Interestingly, the NP group had 
a notable percentage of KLRG1+ CD127- cells, which represented up to 29.9% of the 
memory pool (Fig2-4, C). 
 
 
Figure 2–4 Nanoparticle-peptide and DC-peptide vaccination promote stable CD8 T cell 
memory pools with distinct phenotypic characteristics. A) Immunization timeline and vaccination 
groups. B) Frequency of Thy1.1+ P14 cells of total CD8 T cells in peripheral blood after NP-GP33 and 
DC-GP33 vaccination, in combination with CpG-B. The arrow indicates the time of the booster 
immunization. C) Longitudinal analysis in peripheral blood of the expression of the phenotypic markers 
CD127 and KLRG1 in circulating Thy1.1+ P14 cells. 
 
To further understand how the two treatments impact the CD8 T cell response, we also 
compared the activation and memory differentiation phenotype in the spleen and LNs during 
the effector phase after the first immunization. First, we analyzed the proliferation of the CD8 
T cells locally (in draining LNs) and systemically after the immunization. In LNs, the NP 
treatment lead to a significant increase in the number of antigen specific CD8 T cells 
compared to the DC immunization, while in the spleen both immunizations led to the same 
cell counts (Fig2-5, A).   
Examination of the surface markers revealed a comparable downregulation of CD62L, while 
effector and activation markers such as CD44, CD27, CD43 and KLRG1 were upregulated to 
similar levels in both groups.  Analysis of survival factors showed that IL-2R chain (CD122) 
was equally expressed in both groups, whereas the IL-2R chain (CD25) and CD127 were 
expressed in lower levels after vaccination with NPs.  Surprisingly, we found an increase in 
the expression of PD-1 in CD8 cells primed by NPs. PD-1 is associated with T cell 
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exhaustion in various chronic diseases, although it is also associated with T cell activation 
(Fig2-5, B) 26–28.  However, we did not observe overexpression of other co-inhibitory 
molecules, such as LAG-3 (data not shown).  
 
Figure 2–5 Immunization with NP-GP33 and DC-GP33 immunization differentially regulated 
effector CD8 T cells. A) Naïve mice were vaccinated on day 0 with NP-GP33 and DC-GP33,, together 
with CpG-B, and CD8 T cell responses were evaluated on day five after immunization. NP-GP33 
promoted a strong proliferation of Thy1.1+ P14 cells in draining LNs, while DC-GP33 promoted a better 
Th1.1+ P14 expansion in the spleen.  B) Differences in the expression of markers and survival 
receptors between NP-GP33 and DC-GP33 groups at day five after immunization. C) Lymphocytes from 
lymph nodes and spleens were isolated and restimulated ex vivo with GP33; cytokines were assessed 
by intracellular staining. D) In vivo cytotoxic assay; untreated (CFSE low) and GP33 pulsed (CFSE 
high) splenocytes were administered intravenously (i.v.)  into mice vaccinated four days early with NP-
GP33, DC-GP33, soluble GP33 or untreated mice.  After 9 hours, splenocytes were isolated, and 
assessed by the presence of CFSE low and CFSE high cells.  
 
To evaluate and compare the functionality of the CD8 T cells induced by the two treatments, 
we restimulated splenocytes and LNs cells ex vivo, and assessed their cytotoxicity and 
polyfunctional capacity. We observed that almost all the expanded cells secreted IFN in 
both groups, locally and systemically.  However, CD8 T cells educated following NP 
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vaccination were less polyfunctional than those generated following DC vaccination, as 
observed by a decrease in the percentage of IFN and TNF secreting cells, in both spleen 
and draining LNs (Fig2-5, C). Moreover, an in vivo cytotoxicity assay showed similar killing 
activity in both groups, as measured by the deletion of target splenocytes labeled with a high 
concentration of CFSE (Fig2-5, D). In summary, these data indicate that both vaccinations 
promoted functional CD8 T cells, albeit through distinctive activation pathways that altered 
their differentiation fate: NP vaccine biased towards a KLRG1+CD127- phenotype, and DC 
vaccine towards a KLRG1-CD127- phenotype. 
 Nanoparticles–peptide immunization promotes a stable pool of memory CD8 T 
cell with an effector-like phenotype 
The goal of vaccination is to promote the generation of long-lasting memory CD8 T cells. 
However, there is contradictory evidence regarding which phenotype correlates the best with 
protective immunity.  Hence, to gain a comprehensive description of the memory CD8 T cells 
induced by the NPs, we assessed the expression of common “central” vs “peripheral” 
markers, such as KLRG-1, CD62L, CD44 and CD127 7,25,29,  as well as a new scheme 
proposed by Hikono et al, and reported by others 12,13, where instead of the usual division 
based on the trafficking patters of the CD8 T cells, the different memory subpopulations are 
divided based on the expression of the activation marker CD27 and the activated glycoform 
of CD43.  
Following vaccination with a control DC vaccine (as above) or with the NP vaccine, antigen-
specific CD8 T cell responses were assessed in several organs known to harbor significant 
populations of immune cell infiltrates. As expected from the frequency of antigen specific 
CD8 T cells circulating in blood, the numbers of P14 cells residing in secondary lymphoid 
organs (LN, spleen) where significantly higher when vaccinating with NPs compared with 
DCs (Fig2-6, A).   
Next, we evaluated the phenotype of P14 cells in LN, spleen, liver and lung. Interestingly, in 
LNs, the proportion of antigen-specific CD8 T cells expressing CD127 was similar in both 
groups. Likewise, both treatments promoted CD8 T cells with high expression of CD27, 
although the NP-primed P14 cells displayed lower frequencies of CD43 than their DC-
educated counterparts (Fig2-6, B). In contrast, we found notable differences in the memory 
phenotype in spleen, liver and lungs. In these organs, the NP group displayed at least a 10-
fold increase in the frequencies of CD127lowKLRG-1hi cells, similar to what it is observed in 
the blood (Fig2-6, C). There were also notable differences in the expression of CD27 and 
CD43. NP immunization had a memory pool dominated by a CD43-CD27- (DN) population, 
while the DC vaccination promoted a much higher frequency of CD43+CD27+ (DP) cells. 
These populations phenotypically resembled those reported by Hikono et al and Olson et al 
12,13, as the DP set express prototypical markers of central memory, and DN cells express 
low levels of CD62L, CD127 and high levels of KLRG-1 (Fig2-6, B-D). Although not further 
explored in this thesis, we observed a fourth population characterized by CD27-CD43+, 
which has not been previously reported in the literature.  We do not believe this is an artifact 
from the experiment, since the population is restricted to the NP group, and was never seen 
in the DC treatment.  
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Finally, motivated by the dissimilarities in the PD-1 observed on the T cells following NP 
vaccination during the effector phase of the response, we evaluated whether the differences 
are maintained until the memory stage. Notably, almost all NP-primed specific CD8 T cells 
conserved PD-1 expression in both spleen and LN, while the DCs showed PD-1 levels 
similar to those on naïve T cells (Fig2-6, F). These results suggest that PD-1 expression was 
conserved from earlier activation. 
 
 
Figure 2–6 NP-GP33 promotes an effector like phenotype upon a prime-boost immunization. A) 
Left, Immunization timeline and vaccination groups. Right, numbers of Thy1.1+ P14 cells in lymph 
nodes and spleen at day 90 after the first immunization B-C) Phenotype of Thy1.1+ P14 cells in 
secondary lymphoid organs and peripheral organs at day 90 post immunization, based on the 
expression of CD27 and CD43; and on the expression of CD127 and KLRG1. D) Comparison of the 
expression of CD44 and CD62L markers in splenocytes. E) Characterization of the CD43+CD27+ and 
CD43-CD27- subsets in Thy1.1+ P14 cells isolated from splenocytes based on the expression of 
CD62L, KLRG-1 and CD127. F) PD-1 expression of memory Thy1.1+ P14 cells in lymph node and 
spleen.   
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 Phenotype of memory CD8 T cells responses does not depend on the antigen 
dose  
The notable differences in the effector phenotype prompted us to evaluate whether the 
varying the antigen dose has an effect in instructing the CD8 T cells to adopt a certain 
phenotype. Therefore, we vaccinated naïve mice (which received P14 cells) with two doses 
of peptide (0.5µg and 5µg) conjugated onto NPs, and for the DCs we varied a) the 
concentration of peptide delivered to them in vitro or b) the number of DCs used for 
immunization, keeping constant the amount of pulsing peptide. 
For the NP group, the numbers of antigen-specific cells varied according to the amount of 
antigen administered. For the DC group, the number of CD8 T cells correlated especially with 
the number of DCs injected, rather than with the concentration of peptide used during 
pulsing.  However, none of the doses tested appeared to have a significant effect on the 
phenotype. Thus, in our system the dose has an important effect on the magnitude of the 
response, although it does not impact the phenotype of the CD8 T cells (Fig2-7, A-B). 
 
 
Figure 2–7. Phenotype of memory CD8 T cells upon NP-GP33 and DC-GP33 immunization is 
independent of the peptide dose and the DC-cell number administration. A) Frequency of 
Thy1.1+ P14 cells from total CD8 T cells in lymph nodes and spleen 90 days after the first 
immunization. B) Phenotype of Thy1.1+ P14 cells in lymph nodes and spleen based on the expression 
of CD27 and CD43; and on the expression of CD127 and KLRG1.  

32
 NP-induced memory CD8 T cells with high KLRG1 expression are not senescent, 
and respond vigorously to an ex vivo antigen restimulation and to an in vivo viral 
challenge 
To characterize the functional properties of the two different types of memory T cells, we 
evaluated cytokine secretion in response to restimulation with GP33  ex vivo at day 90 (Fig2-8, 
A). Interestingly, in LNs, the proportion of cells with multiple cytokine secretion varied largely 
between both groups, despite of both memory CD8 T cells displaying a similar phenotype in 
this organ. NP and DC primed P14 cells were capable of strong IFN secretion (89% and 
78%), although the NP group generated lower levels of dual-cytokine secreting cells (IFN 
and TNF) than the DC group (62% vs 37%). In the spleen, instead, both groups displayed a 
similar cytokine secretion capacity as that observed earlier during the effector phase 
response with almost all of the cells secreting IFN, and a large proportion secreting both, 
IFN and TNF  (62% and 82% for NPs and DCs) (Fig2-8, B).  
 
 
Figure 2–8 Expression of effector molecules by memory CD8 T cells after NP-GP33 and DC-GP33 
immunization. A) Lymphocytes isolated from lymph nodes and splenocytes at day 90 after the first 
immunization were restimulated ex vivo with GP33,;  cytokine expression was measure by intracellular 
staining 6 hours after restimulation in the presence of Brefeldin A. B) IFN and CD107a expression by 
KLRG-1+ Thy1.1+ P14 cells isolated from splenocytes. C) Antigen specific cytotoxicity; memory 
Thy1.1+ P14 cells were purified by flow-assisted cell sorting and incubated with GP33-targeted 
splenocytes during 4 hours.   
 
Since KLRG-1 expression has been associated with T cell senescence, we also evaluated 
IFN secretion by KLRG1+ cells, and found that in both groups, these cells can secrete IFN 
and cytokines associated with cytotoxicity equally well to the KLRG1- cell subset (Fig 2-8, C).   
We also wanted to explore in a cell-based manner how memory cells in both groups 
responded to a viral infection. For this, we sorted Thy1.1+ P14 CD8 cells from both, the NP 
and DCs group, and transferred them (5x104 cells) into a naïve host. We challenged the mice 
with 2.5x105 p.f.u. of LCMV-Arm i.p.,  and five days post infection evaluated the response of 
P14 cells by assessing proliferation, cytokine secretion and viral titers (Fig2-9,A).  
Assuming that 10% of the transferred cells engraft in the spleen after the adoptive transfer 30, 
we detect more than 7 rounds of division in both groups.  There was a two-fold higher cell 
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number in the cells from the DC immunization over the NPs, as expected given that DC 
vaccination generated a high proportion of P14 cells that resemble a Tcm- like phenotype 
7,9,11–13,31,32 (Fig2-9, B).  Nevertheless, we found no differences in the expression of effector 
molecules such as IFN, TNF or GranzymeB (Fig2-9,C-D).  There were also not differences 
in the viral burden in the kidneys between the DC and NP groups, although very low titers 
were also detected in the mice that did not received P14 cells (Fig2-9, E). This suggests that 
the WT mice are inherently capable of generating robust endogenous responses to LCMV, 
and thus prevented the observation of further improvements in viral clearance due to the 
transferred cells. It would be perhaps better to use immunodeficient mice in order to assess 
the protective capacity of the memory cells in the context of an infection with LCMV-Arm 
 
 
Figure 2–9. Functionality of memory Thy1.1+ P14 cells after viral challenge.  A) Memory Thy1.1+ 
P14 were sorted and 5x104 cells were administered i.v. into naïve mice and challenged with LCMV 
Arm (2x105 p.f.u.). B) Cell counts of Thy1.1+ P14 cells in splenocytes five days after viral challenge. 
C) Cytokine secretion by adoptively transferred Thy1.1+ P14 cells after viral challenge assessed by 
intracellular staining after ex vivo restimulation with GP33. D) MFI of Granzyme B (GrB) expression by 
adoptively transferred Thy1.1+ P14 cells after viral challenge.  E) Viral titers in kidneys were 
determined by a plaque-forming units assay five days after viral challenge 
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2.5 DISCUSSION 
Herein, we have implemented a subunit vaccine based on the PEG-PPS nanoparticle 
platform for the delivery of the MHCI restricted peptide from LCMV, GP33-41. We have 
characterized the CD8 T cell response comparing to the unformulated peptide, as well as 
benchmarking to a well-established DC-based peptide vaccine. 
We observed quantitative and qualitative differences in the CD8 T cell response. In terms of 
quantity, the NPs promoted a significant increase in the frequency of endogenous antigen 
specific CD8 T cells compared to the soluble peptide. These differences were more evident 
in draining LNs, which in agreement with previous reports 33–37, suggests that the NPs 
promote antigen retention in local draining sites, thus enhancing antigen uptake and 
crosspresentation by professional APCs.  
Qualitatively, NPs promoted P14 cells that phenotypically resemble SLECs upon a single 
immunization, characterized by a strong population of KLRG1+ cells at day 6. In contrary, at 
this time the DC vaccine displayed a larger population of cells with MPECs characteristics. 
Various factors could account for these differences. For instance, it has been demonstrated 
that a strong and prolonged antigen presentation to CD8 T cells induces a differentiation to 
effector cells 5,8,10,38,39. Thus, antigen retention, as facilitated by the NP loading, is expected 
to promote an effector-like phenotype, which is in agreement to what we observed in our 
studies.  
Moreover, we speculate that a dissimilar inflammatory milieu during the T cell priming is also 
causing the different phenotypes observed following vaccination with NPs or DCs 8,40,41. 
Although we did not measure the cytokines after the primary immune response, we infer from 
the activation phenotype of T cells that both T cells experience different microenvironments. 
For example, the expression of CD25 (the IL-R2) is maintained by a positive feedback loop 
via enhanced IL-2 signals. Although IL-2 has been described to typically peak at day 1 and 
fade by day 3 (together with the expression of CD25) after viral infection 42,  the expression 
of CD25 on the DC group could be indicating different IL-2 kinetics upon priming in this 
group. Furthermore, the capacity of NPs to target a broad range of antigen presenting cells 
APCs is also a factor that might influence the T cell phenotype, since migratory as well as 
resident DC subsets have different abilities of cross-presentation as well as unique 
expression of costimulatory and/or inhibitory molecules 43.  
Likewise, the lack of CD4 T cell help during the immunization could have influenced the 
strong effector phenotype after the NP immunization. Studies in MHCII knockout mice or 
CD4 deficient mice have reported that unhelped memory CD8 T cells display a phenotype 
consistent to that of the P14 cells reported here following NP vaccination, characterized by 
the lack of CD62L-, CD127- , CD27-, and high levels of KLRG1 44,45.  This, however, does 
not explain why the DC vaccine does not promote the same phenotype. In fact, we have 
observed during the ex vivo restimulation assay IFN secretion by CD4 T cells in the DC 
group (data not shown), while not in the NP immunization. It is likely that CD4 T cell 
activation could have been prompted by MHCII presentation of bovine serum peptides 
carried in the DCs, since this is the usual culture medium for BMDC formation.   
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The NP vaccination also promoted the survival of P14 cells with an effector like phenotype in 
the memory phase. Based on the CD43 and CD27 expression, up to 49% of the P14 cells in 
the spleen were CD43-CD27-, which also displayed low CD127 and CD62L levels, but high 
KLRG-1 expression. The survival of this effector-like memory subset has been reported in 
various studies that employ diverse immunization models. For instance, Hansen et al 39 
reported that a vaccine against simian immunodefficient virus (SIV) based on a rhesus 
cytomegalovirus (RhCMV)- vector induced long-lived memory T cells with effector-like 
properties. Similarly, Reyes-Sandoval et al 10 described that an immunization with an 
adenovirus based vector encoding Malaria antigens left a memory population of effector CD8 
T cells with low CD62L and CD127 expression. Interestingly, in both studies the induction of 
the effector-like characteristics on CD8 T cells was acknowledged to the ability of the vectors 
to promote persistent antigen delivery. Moreover, in both immunization models, the 
protection against their respective pathogen challenges correlated with the presence of the 
effector memory T cell subset. 
We also observed an increase in PD-1 expression on NP-primed memory CD8 T cells, 
although no other inhibitory receptors, such as LAG-3. PD-1 is often associated with 
exhausted cells, however in our system, PD-1+ cells were able to respond to a booster 
immunization.  Although the literature is clear in that not all the PD-1+ cells are exhausted, 
there are very few studies addressing the role of this ligand in memory differentiation 46,47.  
Hokey et al  47 showed  that peptide vaccination in macaques also drives the expression of 
fully active PD-1+ cells, indicating that rather than being a marker of exhaustion, PD-1 
expression defines T cell activation during a primary immune response. PD-1+ cells have 
also been suggested to be a unique subset derived from chronic infections that have 
undergone a special differentiation pathway to reach a unique state where viral control is 
enhanced without excessively damaging the host.  Since NPs promote antigen retention in 
the draining lymph nodes, it is likely that the antigen persistence is causing the PD-1 
expression, resembling somehow a chronic infection 48.  
We demonstrate that the effector memory P14 cells elicited after NP vaccination were 
functional and responded vigorously to an ex vivo antigen restimulation and a viral challenge 
by secreting effector molecules (IFN, TNF, GrB) in similar levels to those observed by the 
Tcm-like memory cells induced after the DC vaccination. Although we could not evaluate 
which of the two subsets promoted better protection in the context of an acute LCMV 
infection, we hypothesized that protection against a pathogen would most likely require 
different types of T cell memory, and this would have to de determined on individual basis. 
Moreover, we conceive that establishing a correlate of protection would require a 
comprehensive description of the T cell memory phenotype, the magnitude of the T cell 
memory pool, the effector capacity of the T cells and their location in lymphoid organs and 
peripheral tissues. 
  
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3.1 ABSTRACT 
Nanoparticle-based delivery systems are known to enhance the immune response to soluble 
antigens, thus standing as a promising tool for the development of new vaccines. In our 
group, we have engineered two different particulate systems in which antigen is either 
encapsulated in the core (polymersomes, PSs) or decorated onto the surface of 
nanoparticles (NPs). Previous studies demonstrated that PSs are better enhancing CD4 T 
cell responses, while NPs preferentially augment cytotoxic CD8 T cell responses. Herein, we 
demonstrated that the distinct activation of the T cell immunity reflects two modes of 
intracellular trafficking, as well as a differential biodistribution of the antigen in lymphoid 
organs, which is promoted by the properties of the nanocarriers.  
Furthermore, we found that PSs promoted a better CD4 T cell activation, and induced a 
higher frequency of CD4 T follicular helper cells (Tfh). The differences in CD4 Tfh cell 
responses correlated with changes in germinal center B cells and plasma cell formation. 
Moreover, when evaluating the long-term antibody response, we demonstrated that both 
vectors promoted comparable levels of serum antigen specific IgG titers. Nevertheless, the 
humoral responses to both vectors varied qualitatively, with PSs skewing the antibodies 
towards a Th1-like phenotype, and NPs towards a Th2-like phenotype.  
Taken together, these results demonstrate that nanocarriers have a deep impact on the 
quality of the adaptive immune response. It also suggests that PSs are a promising vector for 
the delivery of antigens for B cell vaccine development, since PSs promote robust CD4 Tfh 
cells responses and corresponding GC B cells. Additionally, it removes the need to 
chemically modify the antigen, which simplifies the development of new subunit vaccines. 
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3.2 INTRODUCTION 
Vaccination is undoubtedly a major success in modern medicine, and stands as an 
affordable and safe technology that has allowed the control and eradication of life threatening 
diseases 1,2.  Yet, today there are pathogens that account for more than a million deaths 
annually, for which no licensed or fully protective vaccines have been created 3,4.  
Development of vaccines based on subunit components has proven to be a safe and cost 
effective method for eliciting protection against pathogenic infections.  It erases safety 
concern related to immunization with live attenuated viruses, and it offers the flexibility to 
target an specific antigen as well as to tune the quality of the response by selecting a precise 
immunostimulatory compound 5. Still, the ability of subunit vaccines to stimulate an immune 
response is usually weaker than traditional preparations with whole-attenuated pathogens.  
One of the approaches used to enhance immunogenicity of subunit vaccines is antigen 
loading or presentation by biomaterial-based carriers, especially in particulate shapes 6–9. 
Various studies have demonstrated that antigen loading into synthetic particles enhances 
uptake and presentation by professional presenting cells, such as dendritic cells (DCs), as 
well as increases antigen bioavailability by promoting antigen retention in lymphoid organs 10–
16. 
Our group has recently developed two nanocarriers, nanoparticles (NPs) 17,18 and 
polymersomes (PSs) 11,19,  composed by the hydrophobic polymer Propylene sulfide (PPS), 
and by the hydrophilic polymer polyethylene glycol (PEG). Despite of having the same 
building units, both systems differ considerably between each other in their physical and 
chemical properties.  NPs are carriers of 30-50 nm in diameter, and consist of a rubbery 
hydrophobic core of PPS, covered by a corona of PEG where antigen is loaded through 
diverse chemical ligations. Usually, proteins are attached through a disulfide bond (-ss-), as 
our lab has shown that a reducible bond favors crosspresentation to CD8 T cells 7. PSs 
instead are formed to a minimum diameter of 150-170 nm, and constitute a vesicle 
surrounded by a polymeric bilayer of PEG-PPS.  In such a conformation, hydrophobic 
compounds are loaded into the amphiphilic bilayer, while hydrophilic compounds are 
encapsulated into the aqueous core.  This platform allows for antigen release in vitro in an 
oxidative dependent manner, which is likely happening in harsh condition inside DCs, such 
as those found in the lysosomes 11. 
Interestingly, the difference in design between the two particulates significantly affects innate 
and adaptive immune responses. Recently, Stano et al 20  demonstrated that PSs are better 
at enhancing CD4 responses, while nanoparticles preferentially enhanced the induction of 
cytotoxic CD8 T cells. The exact mechanisms by which a particulate enhanced a specific 
type of response are still unknown.  Based on the way antigen is presented and released to 
professional presenting cells, it is probable that differences in antigen processing at the 
cellular level account for the distinct immune responses 21.  Particle size should also impacts 
the lymphatic transport, as well as the nanocarrier distribution in lymphoid organs, and 
therefore targeting to specific DCs populations.  
In this study we investigated how the model antigen chicken egg ovalbumin (OVA) 
formulated in NPs (NP-ss-OVA) and PSs (PS(OVA)) differ at the cellular and at the organ 
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level in terms of intracellular trafficking and cellular uptake. Our data demonstrates that 
antigen in PSs is delivered preferentially to lysosomes, while a fraction of the antigens on 
NPs undergo endosomal escape. At the organ level, NP-ss-OVA and PS(OVA) have a 
differential lymphoid organ distribution and uptake by DCs. Furthermore, we show that 
PS(OVA) enhanced the formation of T follicular helper CD4 responses, which correlated with 
an increase in germinal center cells (GCs) and plasma cell formation.  These differences 
where reflected in the quality of the humoral response, with PS(OVA) skewing the antibodies 
towards a Th1-like-phenotype and NP-ss-OVA towards a Th2-like phenotype. 
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3.3 MATERIALS AND METHODS 
Animals 
C57BL/6 female mice, age between 8-12 weeks, were purchased from Harlan (France). 
Thy1.1+ OTII mice were obtained from an in house colony. All animal experiments were 
performed under the approval from the Veterinary Authority of the Canton of Vaud 
(Switzerland) according to Swiss Law.   
Nanoparticle preparation 
All chemical reagents were reagent grade and purchased from Sigma-Aldrich unless 
otherwise stated. Nanoparticles (NPs) were prepared as described in chapter 2, with some 
modifications to allow for protein loading into the PEG corona 22. Briefly, a mixture of 1:3 
COOH-PEG / OH-PEG was used to prepared the emulsion polymerization to form NPs. After 
exposure to air for 2 hours, the remaining thiolates were quenched by the addition of 45 mg 
of iodoacetamide and stirred for 15min. To functionalize the COOH groups in the NP surface, 
sulfo-NHS (Life Technologies), Pyridyl disulfide cysteamine (synthesized in house) and 1-
Ethyl-3-(3-dimethylaminopropyl) (EDC) were added to the mixture and let to react for 24 hr. 
For purification, NPs were dialyzed against MQ H20 for 36 hour at room temperature by 
replacing the water every 6 hrs, and passed through a filter with a 0.22 µm pore size 
(Millipore Corporation). The concentration of the loaded pyridyl disulfide was determined by 
measuring the absorbance at 340 nm after adding TCEP (ThemoScientific) to the NPs 
solution.  
For Ovalbumin (OVA) loading, 500 µL of NPs were mixed with 286.6 mg of guanidine 
hydrochloride (GndHCl) to achieve a final concentration of 6M of GndHCl. The solution was 
filtered through a 0.22 µm membrane (Millipore Corporation) and mix with 50µL of OVA at 40 
mg/mL.  The mixture was left overnight at room temperature, and then purified by size 
exclusion chromatography through a Sepharose CL-6B column equilibrated in 50mM sodium 
phosphate. The concentration of OVA in the fractions obtained after purification was 
determined by a BCA assay following the manufacture’s instructions (ThermoScientific).  
Before and after the coupling, the size of NPs was determined by dynamic light scattering 
with a Nano Zs Zetasizer (Malvern Instruments). The diameter of NPs varied between 35 
nm-40 nm. 
Block-copolymer synthesis and polymersomes preparation 
All chemical reagents were reagent grade and purchased from Sigma-Aldrich unless 
otherwise stated. Polymersomes (PSs) were prepared following the original description in 23.  
Block-copolymers were synthesized using benzyl mercaptan to start the living polymerization 
of propylene sulfide. The terminal thiolates were capped with PEG-mesylate.  For 
purification, the co-polymers were precipitated two times in cold methanol. The purity and 
length of the PPS chain were confirmed by gel chromatography and by NMR. Usually, chains 
of PEG17-bl-PPS x, containing between 26-32 PPS units were used to form PSs.  An amount 
of 30-50mg resuspended in DCM was placed in piranha-etched glass vials and desiccated 
overnight. For the formation of PSs, the formed thin-film of copolymer was rehydrated with a 
solution of 5 mg/mL of OVA or fluorescently labeled OVA in 50 mM phosphate buffer, and let 
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rotating for 48 hrs at room temperature.  Afterwards, the solution was extruded at least 4 
times through a 0.2 µm nucleopore track-etched membranes (Whatman) to obtain PSs 
ranging between 150 nm-170 nm, with polydispersity values lower than 0.2. Purification of 
the unloaded molecules was achieved by size exclusion chromatography trough a 
Sepharose CL-6B column. Fractions containing PSs were pull together and further 
concentrated though an Ultra-centrifugal filter (Millipore Corporation) with a cutoff of 100kDa. 
Final OVA loading was quantified by a sandwich ELISA as described by Stano et al 20.  
The size of PSs was determined by dynamic light scattering with a Nano Zs Zetasizer 
(Malvern Instruments). 
Immunizations and adoptive transfers 
All vaccines were administered intradermally (i.d.) into the 4 limbs. 10 µg of OVA were 
injected per mouse for all formulations, unless otherwise stated, together with 10 µg of CpG-
B (Microsynth). Before the immunizations, OVA was filtered through a 0.22µm membrane 
(Millipore Corporation) to remove aggregates.  Furthermore, all formulations were tested for 
LPS contamination using a TLR activation HEK-Blue LPS detection assay (Invivogen).  
For adoptive transfers of naive TCR transgenic CD4 T cells, single cell suspensions were 
prepared from spleens of OTII Thy1.1+ mice. CD4 T cells were isolated using the EasySep™ 
Mouse CD4 T Cell Isolation Kit (Stemcell Technologies). Immediately after isolation, 2x106 
cells were adoptively transferred i.v. into naïve host mice.  
ELISAS 
For the detection of antigen specific antibodies, 96-well Nunc MaxiSorp® plates were coated 
with 5µg/mL of OVA overnight at 4°C. Plates were washed 3 times with PBS / 0.02% Tween-
20 and block using a 2.5% casein solution in PBS for 2 hours at room temperature. Serial 
dilutions of serum in casein were added to the blocked plates for 2h at room temperature.  
Plates were washed 4 times and mixed with detection antibodies against IgG1, IgG2, IgG3 or 
total IgG (Southern Biotech). All secondary antibodies were conjugated to horse radish 
peroxidase. After 1h incubation; plates were washed 4 times and developed using 50 µL of 
TMB (eBiosciences). Signal was stopped by adding 20µL of 2N H2SO4.  Plates were 
analyzed using a plate reader spectrophotometer (Tecan) by measuring the absorbance at 
450nm with correction at 570nm. 
Generation of bone marrow derived DCs  (BMDCs) 
Bone marrow derived CD11c+ dendritic cells (BMDCs) were generated by adapting the 
protocol described by Lutz et al 24. Briefly, BM cells were cultured for 8-9 days in the 
presence of 20 ng/mL of GM-CSF, changing the medium every 3 days.  After this time, 
CD11c+ cells constitute the 70-85% of the non-adherent population.   
Preparation of lymph node and spleen suspensions 
For the biodistribution study, lymph nodes were opened with needles and first digested in 
DMEM (1.2mM CaCl2, 2% FBS, Pen/Strep) containing collagenase IV (1mg/mL) and DNAse I 
(40 µg/ml) to isolate lymphocytes. In a second digestion step with DMEM with collagenase D 
(1mg/mL) and DNAse I (40 µg/ml), stromal lymph node cells were isolated for further 
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analysis. In the remaining experiments, lymph nodes were opened with needles and digested 
in DMEM (1.2mM CaCl2, 2% FBS, Pen/Strep) containing collagenase D (500 µg/mL). After 
digestion, lymph node cell suspensions were filtered through a 70 µm nylon cell strainer.  For 
spleen, single cell suspensions were prepared by mechanical disruption through a 70µm 
nylon cell strainer. Splenocytes were further treated with hypotonic ammonium chloride–
potassium bicarbonate buffer to lyse red blood cells.   
Ex vivo reestimulation 
Up to 3x106 cells were plated in 96-well plates and cultured in 10%FBS -DMEM medium for 2 
hours at 37°C in the presence 200 µg/mL of OVA. Afterwards, 5 µg/mL of Brefeldin A were 
added to the culture and left for 3 extra hours.  
Flow cytometry 
Up to 3x106 cells were plated in 96 well plated and wash once with HBSS for staining with 
live/dead fixable cell viability reagent (Life technologies). For surface staining, cells were 
washed once with HBSS supplemented with 0.5% bovine serum albumin (BSA, Sigma) 
(staining buffer) and resuspended in an antibody cocktail using monoclonal antibodies.  
Detection of follicular helper cells T cells was achieved in a 2-step process. First, cells were 
incubated with CXCR5-biotin (eBiosciences) in staining buffer for 30 min, washed once and 
then incubated with an antibody cocktail with Streptavidin-647 (Biolegend) and the remaining 
antibodies. For intracellular staining, cells were fixed and permeabilized with the Foxp3 / 
Transcription Factor Fixation/Permeabilization kit (eBiosciences) according to the 
manufacturer’s instructions. After staining, cells were resuspended in staining buffer for 
analysis by flow cytometry.  
Data collection 
Flow cytometry was performed using a CyAnTM ADP (Beckman Coulter) and data were 
analyzed with FlowJo (Tree Star). We used the non-parametric Mann-Whitney U test or 1-
way ANOVA, followed by a Bonferroni post-test to find differences between the groups. A P 
value of less than 0.05 was used as an indicator of statistical significance.  All data was 
analyzed using the GraphPad Prism 5 Software (GraphPad Software Inc., La Jolla, CA).   
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3.4 RESULTS 
 Nanoparticles and Polymersomes promote a distinct intracellular antigen 
trafficking in dendritic cells  
The intracellular route of antigen is known to play a role in driving CD4 or CD8 T cell 
responses 25,26. Therefore, to understand if intracellular trafficking takes part in differential T 
cell activation by the two particulate carriers, we incubated bone marrow derived dendritic 
cells (BMDCs) together with PSs and NPs loaded with fluorescently labeled OVA, and 
evaluated their colocalization with markers associated with endosomal or lysosomal 
compartments, such as the early endosome antigen 1 (EEA1), and the lysosomal-associated 
membrane protein 1 (LAMP1).    
After incubation of NP-ss-OVA and PS(OVA) with BMDCs for 2hrs, we began to observe a 
high colocalization of PS(OVA) within LAMP1+ vesicles in the perinuclear space, but a much 
lower association with EEA1 (Fig3-1, A, left; Fig3-1, B).  Instead, NP-ss-OVA colocalized 
more with EEA1+ endosomes compared to PS(OVA) (Fig3-1, B). Although the percentage of 
colocalization with LAMP-1 compartments for the NP group was similar to that one found for 
the PSs, qualitatively we noticed than the antigen was more dispersed throughout the cell 
rather than located in proximity of the perinuclear space in association with LAMP1+ vesicles 
(Fig 3-1 A, right; Fig3-1, B).  
Early work in our group 7 showed that the vehicle alone (NPs, no antigen) aggregated in the 
perinuclear space and exhibited a high degree of LAMP1+ colocalization. Thus, our finding 
that NP-ss-OVA colocalized with early endosomes suggests that when the antigen is 
incorporated into the carrier, a fraction of it is cleaved during intracellular trafficking, allowing 
for endosomal escape into the cytoplasm.    
Subsequently, we calculated the ratio of colocalization between LAMP1 and EEA1, and 
found that the distribution of OVA when delivered through NPs exhibited an approximate 1:1 
ratio between late and early endosomal compartments whereas the OVA inside PSs 
displayed a nearly 6:1 ratio of LAMP1+ to EEA1+ vesicular colocalization (Fig 3-1, C).   
Taken together, this data demonstrates that OVA loading into nanocarriers impact the final 
location of the antigen. It suggests that antigen loaded within PSs carriers may be precluded 
from early endosomal escape and subsequent early cytosolic processing, and thus traffics 
through LAMP1+ late endosomal or lysosomal compartments. This intracellular route is 
typical of exogenous antigen processing and has been shown to lead to MHCII presentation 
27. Meanwhile, the differences in the relative distribution of NP-ss-OVA and NP delivery 
vehicle alone observed in earlier work suggests that a fraction of antigen escapes into the 
cytoplasm, where it is processed by the machinery associated with MHCI presentation.   
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Figure 3–1. Intracellular trafficking of OVA-64 after loading into Nanoparticles (NPs) or 
encapsulated within polymersomes (PSs). A) NP-ss-OVA and PS(OVA) were incubated with 
BMDCs during 2h at 37°C. Cells were stained for the early endosome antigen 1 (EEA1) and for 
lysosomal-associated membrane protein 1 (LAMP1) to evaluate the intracellular trafficking of OVA. B) 
Percentage of colocalization of NP-ss-OVA or PS(OVA) with either EEA1 or LAMP1.  C) Ratio of the 
percentage of colocalization with LAMP1 o EEA1 reveals the relative distribution of OVA within these 
intracellular compartments. Data courtesy of Aaron Mayer.   
 
 NP-ss-OVA are associated preferentially with CD8+ DCs and migratory DCs, 
while PS(OVA) are preferentially associated with lymph node resident 
CD11b+CD11c+ cells 
We wanted to evaluate whether the differences observed in cellular responses were also 
attributed to a differential organ distribution and cellular uptake by dendritic cells (DCs). 
DCs are crucial for the initiation of T cell responses in the lymph node (LN) 28. Several 
subsets of DCs have been identified, including lymphoid tissue resident DCs, which locate in 
their majority in close contact with the LN conduit system to rapidly take up draining antigens 
29–33; and the migratory DCs, which travel from peripheral tissues via afferent lymphatics, and 
carry antigen from distal sites for its transfer to resident DCs or for its presentation to 
lymphocytes 28,31,33–38.  
To investigate the early events of antigen acquisition by DCs, we labeled OVA with a 
fluorescent dye, and immunized mice together with CpG-B. We collected draining LNs at 2 
and 36 hours (hrs) after immunization, and analyzed by flow cytometry the distribution of 
cells positive for antigen at both time points (Fig3-2, A).  After 2 hrs, we observed a 
frequency of OVA+ cells of 6% in the NP group, compared to a 1% in the PSs group. By 36 
hrs, the level of OVA+ cells in LNs was similar in both conditions, displaying a drastic 
reduction for NPs, while a modest increase for the PSs group (Fig3-2, B).  
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Figure 3–2. Lymph node biodistribution of NP-ss-OVA and PS(OVA) after intradermal (i.d.) 
administration with CpG-B. A) Immunization timeline and vaccination groups. B) Left, representative 
flow cytometry plot of OVA+ cells in the viable cell population. Right, frequency of OVA+ cells within 
the viable cell population after 2 and 36 hrs immunization. C) Left, gating strategy of dendritic cell (DC) 
subsets. The flow cytometry plot of MHCII vas CD11c was generated after exclusion of B cells and 
pDCs. Right, frequency of DCs within the OVA+ population at 2 hrs post immunization.  D) Left, gating 
strategy of the lymph node resident DC subsets CD11b+CD11c+ and CD8+CD11c+. Right, frequency 
of lymph node resident DC subsets within the OVA+ population at 2 hrs post immunization. E) 
Frequency of CD11b+ CD11c+ and CD8+ CD11c+ within the OVA+ population at 36 hrs post 
immunization. F) Left, Identification of myeloid derived DCs based on the expression of Ly6C, CD64 
and CD11c.  Right, frequency of myeloid derived DCs within the OVA+ population at 2 hrs and 36 hrs 
post immunization.  
  
Afterwards, we analyzed the various DCs subsets within the OVA+ cells.  For the 2 hrs 
timepoint, we first excluded B cells and identified plasmocytoid DCs (pDCs) based on B220 
and CD11c expression, with B cells as B220+CD11c- and B220+CD11cmid cells as pDCs. 
We also excluded monocytes and macrophages as CD11b+CD11c- 39, and on the remaining 
cells distinguished the migratory and resident DC subsets based in the CD11c and MHCII 
expression 33,40,41.  The migratory cells DCs were classified as CD11cmidMHCIIhi and resident 
DCs as CD11chiMHCIImid. We also found a MHCIImidCD11cmid population, that we called 
intermediate DCs (iDCs). This subset was a quite heterogeneous population containing 
CD103+, CD8+, CD4+, as well as Ly6C monocytes and Ly6G+ cells. This last population 
may potentially be neutrophils that upregulated CD11c expression early after the 
immunization (Fig3-2, C). 
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By 2 hrs, migratory cells present in the LN were the main DCs associated with PS(OVA) and 
NP-ss-OVA (18% and 10%). For the NP group, the iDCs were the second population taking 
up antigen (8%), followed by the resident DCs (7%). For PS(OVA), instead, the resident DCs 
cells display the second highest association (8%), followed by the iDCs (4%). Finally, we 
found very low association with pDCs, consistent with previous description of these cells 
being less efficient APCs 40 (Fig3-2 C, right).  
We were also interested in analyzing the diverse subsets of resident DCs. There is 
increasing evidence that the CD11b+ CD11c+ LN DCs, which reside in close contact with 
cortical and medullary sinuses in draining LNs, are one of the main subset associated with 
MHCII presentation to CD4 T cells 29–31,33,36. CD8+ DCs, on the contrary, are mainly 
responsible of crosspresentation of exogenous antigens to CD8 T cells 37. Therefore, we 
separate the resident subset into CD11b+ DCs and CD8+ DCs. Notably, we found a higher 
association of PS(OVA) with CD11b+ cells (5% for PSs, and 3% for NPs), while NP-ss-OVA 
were observed in higher frequencies in CD8+ DCs  (3% vs 1.5%, Fig3-2, D).  
For the 36hrs timepoint, we analyzed LNs solely based on the expression of CD8+ and 
CD11b+, since the classification used at 2 hrs was not longer possible, as most of the DCs 
have matured and upregulated MHCII and CD11c 42 (Fig 3-2, E). Overall, we found much 
lower OVA+ CD8+ DCs at this time, and a significant association of PS(OVA) and NP-ss-
OVA with CD11b+ DCs. We analyzed whether the CD11b+ were monocyte derived DC, 
which were recently acknowledged to have enhanced MHCII presentation to CD4 T cells 43 
(Fig 3-2, F). Distinction of mDCs from conventional DCs was assessed by the expression of 
CD64, Ly6C and CD11c. Indeed, a prominent population of mDCs was observed after 36 hrs 
post-immunization, which corresponded to the majority of CD11b+ cells at this timepoint. 
However, we did not observe large differences in antigen uptake between NP-ss-OVA and 
PS(OVA) for this population (28% for NPs and 30% for PSs).  
 PS(OVA) and NP-ss-OVA display a differential lymph node biodistribution 
During the last decade, there has been increasing evidence of the role of non-hematopoietic 
cells in antigen presentation to T cells 32,44. Herein, we wanted to evaluate whether antigen 
was associated with LN stromal cells after vaccination with NPs and PSs.  
LN stromal cells are negative for the CD45 antigen. Therefore, we examined CD45- cells at 2 
and 36 hrs after immunization. Within the OVA+ fraction, we observed that PSs and NPs 
displayed a similar frequency of CD45- cells at both timepoints. As expected, the frequencies 
of CD45- at 36 hrs were much lower than the earlier time (Fig 3-3, A).  
We also examined the main LN stromal subsets based on the expression of gp38 and CD31. 
We classified the CD45- cells as blood endothelial cells (BECs, CD31+gp38-), fibroblastic 
reticular cells (FRCs, CD31+gp38+), lymphatic endothelial cells (LECs, CD31+gp38-) and 
double negative cells (DN, CD31-gp38-) (Fig3-3, B). We performed this analysis only for the 
2hrs time, since the frequencies of CD45- cells at 36hrs were to low to obtains a nice 
differentiation of the four stromal subsets.  
Interestingly, there was a significant difference in the distribution of OVA between both 
carriers. When the antigen was delivered by NPs, it was mainly associated with FRCs (54%) 
50
and BECs (27%), and in a lesser extent with LECs (7%). There was also a significant fraction 
of DN cells (12%), although to date it is not clear the location or role of these cells within LNs.  
Conversely, OVA within PSs was found in higher frequencies in LECs (72%), and much 
lower in FRCs (14%) and BECs (7%), as well as DN cells (7%) (Fig3-3, C).  
It is known that soluble molecules with a molecular radius higher than 5-8nm are excluded 
from the reticular conduits found in the LN cortex 45,46. Thus, finding PS(OVA) mainly in 
LECs, while little in FRCs, suggests that this carrier is hold in the subcapsular sinus, and that 
its entry into reticular fibers deep in the lymph cortex is limited due to the larger PSs 
molecular weight 46. However, it is puzzling to find that NP-ss-OVA are so poorly in LECS, 
and strongly associated with FRCs, as well as BECs, which are in connection with the 
reticular fibers in the LN cortex 46. A potential explanation is that a fraction of OVA is cleaved 
from the NPs surface before being internalized, thus allowing for its entry into the reticular 
system.   
Overall, this set of data indicates that each delivery platform has a distinct intranodal antigen 
distribution signature. This differential location inside the LN may promote acquisition of 
antigen by diverse subsets of DCs that reside in specific LN locations, thus contributing to 
the differential cellular responses observed in previous studies.  
 
 
Figure 3–3 Association of NP-ss-OVA and PS(OVA)with lymph node stromal cells populations 
after intradermal (i.d.) immunization with CpG-B A) Frequency of CD45- stromal cell subsets within 
the OVA+ population at 2 and 36 hrs post immunization. B) Identification of stromal cell subsets based 
on the expression of podoplanin (gp38) and CD31. C) Pie charts displaying the frequency of each 
stromal cell subsets within the OVA+ population after 2 hrs immunization with NP-ss-OVA and 
PS(OVA).  
 
 Encapsulation of antigen in PSs enhances T follicular helper CD4 cell responses 
and promotes the generation of germinal center B cells and plasma cells 
Considering the distinct profile of PS(OVA) and NP-ss-OVA in intracellular trafficking, as well 
as cell targeting, and knowing from Stano et al that Th1-like antigen specific CD4 responses 
were higher in mice immunized with PSs, we asked ourselves whether humoral responses 
where also enhanced upon immunization with PSs. First, we evaluated whether vaccination 
with PS(OVA) enhances T follicular helper (Tfh) cell responses. Tfh cells represent a unique 
CD4 T cell subset that specializes in providing help to B cells within germinal centers (GCs) 
51
47, where B cells undergo affinity maturation, class switch recombination, plasma cell 
differentiation, and memory B cell differentiation 47. 
To analyze the induction of Tfh cell responses, we immunized mice i.d. with PS(OVA), NP-
ss-OVA and free OVA, together with 10 µg CpG-B, and at day 9, collected draining LNs and 
spleen. In order to facilitate the detection of Tfh cells, we adoptively transfer 2x106 congenic 
CD4 OT-II cells, which have a MHCII-restricted TCR transgene specific for OVA (Fig3-4, A).   
At this timepoint, PS(OVA) and NP-ss-OVA induced similar OT-II CD4 T cell expansion, 
displaying similar counts in both draining LNs and spleen, while only OVA displayed almost 
100-fold less expansion than the nanocarriers (Fig3-4, B). We then analyzed the phenotype 
of all CD4 T cells (endogenous and adoptively transferred) after NP and PS immunization. 
We found that CD4 T cells primed with PS(OVA) had an enhanced activation phenotype, 
described by a higher frequency of CD44+CD62L- cells. NP-ss-OVA and soluble OVA 
displayed instead similar frequencies of activated CD4 T cells (Fig 3-4, C).  
Subsequently, we quantified the frequency of OTII-CD4 T cells that have adopted a Tfh cell 
phenotype (CXCR5+PD-1+Bcl6+) (Fig3-4, D-E). In LNs, up to 15% of the OT-IIs in the 
PS(OVA) group were Tfh cells, compared to 3% for NP-ss-OVA and 1.8% for soluble OVA. A 
similar trend was seen in the spleen, although the overall frequencies were much lower 
(6.5%, 1.4%, 1.2% for PS, NPs and OVA) (Fig3-4, E). Considering that Tfh cells are 
positively correlated with GCs 48, we analyzed the phenotype of B cells during the same 
experiment. In agreement with previous publications 14,48, we found higher frequencies of GC 
B cells in PS(OVA) immunized mice, with a 2-fold increase over the NP-ss-OVA counterpart 
(Fig3-4, F-H). We also assessed the frequency of plasma cells, which should be in their peak 
of the response in LNs and spleen 49. Once again, the PS group showed an enhancement in 
the frequencies of plasma cells (IgD- CD138+) when compared to the other immunization 
regimes (Fig3-4, G-H). 
All together, these data suggest that the delivery of antigen within PSs results in 
enhancement of Tfh CD4 T cells positively impact important aspects of the humoral 
responses, promoting B cell differentiation into GCs and antibody secreting plasma cells. 
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Figure 3–4. PS(OVA) immunization enhances the induction of T follicular helper (Tfh) CD4 T 
cells A) Immunization timeline and vaccination groups. B) Cell counts of Thy1.1+ OTII cells in lymph 
nodes and splenocytes 9 days after i.d. immunization with PS(OVA), NP-ss-OVA and soluble OVA. C) 
Activation phenotype of all CD4 T cells (endogenous + adoptively transfered CD4 T cells) in draining 
lymph nodes and spleen. D) Identification of Tfh CD4 T cells by flow cytometry ; flow cytometry plots 
were gated on Thy1.1+ OTII cells. E) Frequency of Tfh withing the Thy1.1+ OTII CD4 population after 
immunization in draining lymph nodes and spleen.  F)  Gating strategy of germinal center (GC) B cells; 
B220+ B cells cells were previously gated from viable cells.  G) Representative flow cytometry plots 
displaying GC B cells (up) and plasma cells(down) 9 days after immnunization with PS (OVA), NP-ss-
OVA and soluble OVA. H) Quantification of G, frequency of GCs and plasma cells withing the B220+ 
B cell population. When not indicated,  differences between groups were not significant. * p 0.05 ;  **p 
, 0.01 
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 Polymersomes and nanoparticles promote long-lasting antibody responses  
Based on the observations that GCs and Tfh cells were enhanced with PSs, we sought to 
evaluate the antibody titers upon a prime boost immunization regime, as described by Stano 
et al 20. However, we slightly modified the vaccination regime, by boosting at day 21 instead 
of day 14, since longer intervals between prime and booster immunization has been 
associated with an enhancement of the boosting effect 50 (Fig 3-5, A). 
Mice were immunized with 10µg of OVA as free OVA, PS(OVA), and NP-ss-OVA, together 
with 10µg of CpG-B. Consistent with the previous studies20, a prime boost immunization with 
PS(OVA) enhanced CD4 T cell responses over NP-ss-OVA and free antigen vaccination 
(Fig3-5, B).  
 
 
Figure 3–5 PS(OVA) enhance polyfunctional CD4 T cell responses compared to NP-ss-OVA and 
unformulated protein.  A) Immunization timeline and vaccination groups. B) Cytokine secreting CD4 
T cells in draining lymph nodes and spleen 7 days after a prime-boost immunization with PS(OVA), 
NP-ss-OVA and unformulated OVA, together with CpG-B. Lymphocytes were restimulated ex vivo with 
OVA protein in the presence of Brefeldin A; cytokine expression was assessed by intracellular 
staining.  
 
Afterwards, we evaluated the antibody responses to the vaccination with the diverse 
platforms. Notably, by 3 weeks after a single immunization, the NP group displayed the 
highest levels of IgG antigen-specific antibody titers in serum (Fig 3-6 A, left). This 
observation was quite surprising, considering that this carrier displayed a significantly lower 
CD4 response after an ex vivo restimulation with the full protein, as well as lower frequencies 
of Tfh CD4 cells and GC B cells.  A booster immunization using the same formulation three 
weeks later markedly increase the titers in all the groups, and by day 28 the NP and PS 
groups displayed similar levels of OVA specific IgGs. Free antigen, as expected, promoted 
lower antibody titers than the particulate regimes (Fig 3-6 A, middle).  We also evaluated 
antibody levels at >30 days after the booster vaccination, and found that both NP-ss-OVA 
and PS(OVA) had stable levels of IgG serum antibodies, displaying similar levels to those 
observed by day 28 (Fig 3-6 A, right).  
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Evaluation of the antibody subtypes displays a markedly different response between the two 
carriers. While IgG2c was very high in all immunizations, as expected from the strong Th1 
skewing capacity of the adjuvant CpG-B 51,52, we also found that the NP group display much 
higher IgG1 and IgG3 than PS(OVA) (Fig3-6, B). Analysis of the IgG2/IgG1 and the 
IgG1/IgG2 ratios indicates that in the absence of a carrier, the response is strongly driven to 
a Th1 response. Antigen encapsulated within PSs promotes a more balanced Th1/Th2 
response, but antigen in the surface of NPs promotes a Th2-like skewed response (Fig3-
6,C). Overall, the data demonstrates that particle-based carriers have a strong impact on the 
quality of humoral responses. 
 
 
Figure 3–6 Nanoparticles and Polymersomes qualitatively modify the humoral response to 
OVA. A) Total IgG  OVA-specific serum antibody titers at day 21, 28 and 68 post immunization. B) 
OVA-specific IgG antibody subtypes at day 28, one week after the booster immunization. C) Ratio of 
IgG2c/ IgG1 and IgG1/IgG2c at day 28 after prime/boost immunization. 
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3.5 DISCUSSION 
Particulate-antigen carrier systems are of great interest for the development of subunit 
vaccines. Understanding their mechanisms in cellular targeting and processing as well as 
implications in adaptive immunity is important for vaccine design, as this information would 
be crucial in the decision making process of which carrier would be ideal for an specific 
vaccine application. Previous studies have demonstrated that immunization with PSs 
enhanced CD4 responses, while NPs enhance cytotoxic CD8 T cells. Here, we 
demonstrated that various mechanisms at the cellular and organ level synergize to give rise 
to the opposing responses observed between the two nanocarriers.  
We showed that OVA loaded in NPs upon internalization is partially cleaved in early 
endosomes, allowing for its escape into the cytoplasm and increasing the likelihood of 
proteasome processing and MHCI loading 53,54.  Instead, OVA within PSs displayed higher 
association with lysosomes, where the oxidative environment allows for antigen release and 
loading into the MHCII presentation pathway (Fig 3-7) 55. Such a differential intracellular 
localization might be owed to different modalities of cellular internalization. NPs are known to 
enter the cells through more than one pathway, including macropinocytosis and clathrin-
mediated endocytosis 7. PSs, because of their larger size, are likely being internalized mainly 
by macropinocytosis 25. Interestingly, various studies demonstrated that antigen taken up by 
macropinocytosis is targeted to late endosomal/lysosomal compartments, that are known to 
be specialized for antigen loading in MHCII 26,56–58, which might account for the enhanced 
CD4 responses observed in our experiments. 
At the organ level, we observed a higher amount of antigen draining to local LNs after 
immunization with NPs, when compared to the PSs group.  This data suggests that PSs 
have a lower lymphatic uptake rate than NPs, which could be associated to an increase 
interstitial resistance associated to the larger size and molecular weight of PSs 59. 
Furthermore, we found a differential distribution of the NPs and PSs within the DC 
populations at earlier timepoints after immunization. NPs associated more with migratory 
DCs, which were likely present in the LN (since DC trafficking takes 18h, so it is unlikely they 
capture the antigen on the periphery); and also with LN resident CD8+ DCs. PSs instead 
were more associated with LN resident CD11b+ DCs, and in a lesser extend with migratory 
DCs.  Notably, the CD8+ DCs are mainly associated with the crosspresentation of 
exogenous antigen, while the CD11b+ DCs are related with an enhanced MHCII 
presentation 29–31,33,36,37.  
Despite of the differences in overall distribution, the higher frequency of OVA+ cell in the NP 
group implies that, in terms of cell numbers, the NPs excel in targeting all DC population 
subsets, including the CD11b+ DCs. Given these observations, albeit the differential 
biodistribution, we believe that it is likely that the intracellular processing of antigen plays a 
more important role in directing the T cell response towards CD4 or CD8. Indeed, it has been 
suggested that crosspresentation is not a specialization of DC subsets, rather a process that 
is triggered depending on the way the antigen is presented.  
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Figure 3–7 Intracellular distribution of antigen after coupling to Nanoparticles and 
encapsulation within Polymersomes. Nanoparticles allow for the endosomal release of antigen, 
leading to antigen processing in the cytoplasm by the MHCI presentation machinery. Polymersomes, 
instead, protect the antigen until it reaches the lysosomes, where it is released and loaded into MHCII 
molecules.  

By instance, targeting of antigens through the DEC205 presentation pathway in both, CD8+ 
and CD8- DCs leads to potent crosspresentation to CD8 T cells 60.  Similar results were 
observed with human DCs, were targeting of the antigen to early endosomes through CD40 
or CD11c leads to levels of crosspresentation in BDCA1+ cells (CD8- DCs in mouse) similar 
to those observed in BDCA3+ cells (CD8+ DCs in mouse) 61. Nevertheless, we do not 
disregard the fact that differential uptake of antigen in the LN by migratory DCs as well as LN 
resident DCs contribute to the differential T cell activation. 
Concerning the stromal cell subsets, we observed that antigen in PSs is mainly associated 
with LECs, while antigen in NPs is found mainly in FRCs.  The results might suggest a 
distinct micro-anatomical localization of the antigen, with PS(OVA) associated mainly in 
lymphatic sinuses, while NP-ss-OVA, surprisingly, reaching the LN cortex in association of 
FRCs (Fig 3-8). These observations could also explain the differential uptake observed by 
migratory and resident APCs. Migratory DCs are known to express high levels of CCR762, 
that bind to CCL21 bound to the reticular fiber deep in the T cell area. Therefore, migratory 
DCs are expected to locate mainly in the LN cortex, in close association with FRCs and 
reticular conduits29. Therefore, it is likely mDCs have more access to the antigen that is 
found in FRCs upon delivery in NPs, thus explaining their enhancement of CD8 T cell 
responses. Conversely, PSs are retain in the lymphatic sinuses, where CD11b+ resident 
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DCs sample antigen, as observed by 2-photon in vivo studies 29,30 . This subset, importantly, 
is acknowledged by several studies to enhance CD4 responses 29,30,36.  
 
 
Figure 3–8  Lymph node biodistribution of Polymersomes and Nanoparticles. Antigen loaded 
into nanoparticles can reach the FRC network, where it interacts with LN resident cells such as 
CD11c+ CD8+ DCs. Meanwhile, antigen within PSs is hold on the subcapsular sinus where it is 
sampled by specialized DCs such as CD11b+ CD11c+ cells.  

Two questions arise from these results. First, it is unknown whether the antigens found 
associated in LECs and FRCs are being presented to CD4 or CD8 T cells, and whether this 
has implications on the overall vaccine response. There is strong evidence that these two 
subsets present antigen in both, the MHCI and the MHCII context 32,44,63,64. However, these 
subsets are strongly tolerogenic, and there is little evidence that indicate that they initiate an 
immune response. Secondly, it is still unclear if antigen inside LECs is processed 32,65, or if it 
is transferred intact to other APCs for presentation, similar to what is observed in follicular 
dendritic cells 66. 
We also demonstrated that PS encapsulated antigen promoted better Tfh CD4 responses, 
and increased the formation of GCs and plasma cells early during the immune response. 
There is evidence that the initiation of Tfh CD4 response relies on DC presentation of the 
antigen 67. From the vaccine engineering perspective, it would be exciting to understand 
whether the targeting of a particular intracellular trafficking pathway on DCs enhances the 
formation of Tfh CD4 T cells. This information would be a major contribution to engineering 
principles in vaccine design. Furthermore, it would become conceivable to target antigen to 
specific receptors known to enhance MHCII presentation.   
Conversely, the data obtained for NPs does not fit the classical picture. Despite lower Tfh 
CD4 cells and less GC B cells, this immunization promoted high antibody titers, although the 
quality of the response was considerably different to that observed with PSs. However, 
humoral responses could also develop through the extrafollicualr pathway or in a T 
independent mode, which might be initiated in the absence of GCs and also lead to the 
generation of long lived plasma cells 68,69 . Interestingly, NPs promoted higher titers of the 
IgG3 antibody subtype, which is one of the main IgG subtypes in T independent type 2 
58
responses (TI). Therefore, our previous observations may suggest that the NPs could also 
enhance an extrafollicular route or a TI response. However, this is only a hypothesis, and its 
validation will require further experiments. 
It is clear that antigen formulations have a strong impact on the quality of the elicited immune 
response. Consequently, for particulate vaccine design, consideration of factors such as the 
route of uptake of the antigen, method of antigen release, intracellular trafficking of the 
antigen, size of the carrier and lymphoid organ distribution of the conjugate should be taken 
into account to target a specific immune response.   
In summary, NPs and PSs carriers differ in their immune response to OVA. We conclude that 
modifying the antigen delivery method, i.e, tuning the carrier size and antigen conjugation 
chemistry, has important implications in the quality and quantity of the cellular and humoral 
responses.  For vaccine design considerations, the data suggest that enhancing lysosomal 
targeting of particulate carrier is important in order to enhance CD4 responses. Concerning 
the platforms developed in our group, we conclude that antigen encapsulation in PSs is a 
promising way to deliver antigens for vaccine targeting humoral responses, since it promotes 
robust CD4 responses and corresponding GCs responses without the need to chemically 
modify antigen for loading into delivery vehicles, which simplifies the development of new 
subunit vaccines. 
  
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4.1 ABSTRACT 
 
Lassa hemorrhagic fever is caused by the Lassa virus (LASV), which kills approximately 
5,000-10,000 people yearly. To date, there is single treatment available, Ribavirin, although it 
only has a therapeutic effect when administered early during the infection, Therefore, there is 
clear need of a vaccine or an effective treatment against LASV. In this chapter, we explore 
the feasibility of developing a LASV vaccine targeted to the Lassa glycoprotein 1 (LASV-
GP1), which is believed to be the main target of protective antibodies. We used the 
Polymersomes (PS) platform, based on the capacity of this nanocarrier to enhance antigen 
specific CD4 responses, as well as to promote T follicular helper T cells and germinal center 
B cells. We demonstrated that encapsulation of LASV-GP1 into PSs promotes an 
enhancement of the quality of the elicited antibodies, which had an increased binding to 
LASV-GP1 when displayed in its native conformation and moreover, displayed a broader 
epitope targeting. In summary, our data underscores the effectiveness of nanoparticle-based 
carriers in enhancing qualitatively the immune response to soluble antigens, and suggests 
that a synthetic subunit vaccine against the Lassa fever is feasible.  
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4.2 INTRODUCTION 
Arenaviruses merit significant attention as causative agents of severe hemorrhagic fevers in 
humans. Old world arenaviruses such as Lassa virus (LASV) in Africa and New world 
arenaviruses, such as the South American hemorrhagic fever viruses Junin (JUNV), 
Machupo (MACV), and Guanarito (GTOV) have emerged as important human pathogens 
and represent serious public health problems in their respective endemic areas 1.  
Treatment options for patients infected with pathogenic arenaviruses are very limited. There 
is just a single licensed drug for the treatment of human arenavirus infection, Ribavirin, (1--
D-ribofuranosyl-1,2,4-triazole-3-carboxamide), which is effective when administered at an 
early time during the disease (< 6 days). Since early diagnosis is proven to be a major 
challenge in the endemic locations where the viruses are found (since the symptoms might 
be usually mistaken with other diseases), it is important to develop prophylactic measures to 
reduce the mortality rate of arenavirus-related diseases, which can reach up to 60% during 
epidemic times 2,3.  Nevertheless, to date, there is only one licensed vaccine against 
arenaviruses, specifically JUNV, named Candid No. 1. However, it does not cross-protect 
against important pathogens such as LASV, which of the arenavirus infections, affects the 
most people annually with an estimated of 5000-10000 people dying per year in Africa 4. 
There is little research on developing a LASV vaccine based on humoral responses. 
Protection against Lassa is believed to be mediated mainly by CD8 T cell responses, since 
neutralizing antibodies in surviving patients appear very late after the resolution of the 
infection 2. Furthermore, the information on the protective role of antibodies is controversial. 
For instance, studies in monkey and guinea pigs showed that the passive transfer of 
neutralizing serum from convalescent patients was protective against a lethal LASV 
challenge 5. However, in humans, the passive transfer of antibodies had no effect on the 
control of the disease 6,7. This could be attributed to the difficulty of obtaining high antibodies 
titers for transfer, and also due to the timing of administration, since protection only occurs if 
the transfer happens at the onset of the disease.   
Likewise, the importance of neutralizing antibodies as a mechanism of protection upon 
vaccination is not clear, mainly because of the difficulty to induce protective antibodies 
against LASV. Studies with gamma ray-inactivated Lassa virus failed to promote protection 
despite high levels of antibody titers in the serum of animals 8. Similarly, the majority of 
reports using homologous and heterologous prime-boost vaccinations with viral vectors 
expressing the GP1 and GP2 LASV glycoproteins found low titer antibodies in immunized 
mice with no neutralizing activity 9. However, it is worth noting that several studies did not 
assess the contribution of humoral immunity upon immunizations, as cellular responses were 
considered the main mechanisms of protection 10–12. 
The reasons for the lack of protective humoral responses against glycoproteins of LASV are 
currently unknown. One possibility may be lack of antigenicity of LASV glycoprotein (GP) due 
to extensive shielding by glycans, which is similar to the mechanism of evasion proposed for 
human immunodeficiency virus (HIV) 13. Alternatively, the weak neutralizing antibody 
response against LASV may be caused by hidden immunogenic epitopes within the native 
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trimeric glycoprotein. In this situation, presentation of monomeric components of the surface 
proteins to the immune system could be beneficial for induction of neutralizing antibodies.  
Our group has recently developed a polymeric vesicle composed of copolymers of propylene 
sulfide (PPS) and polyethylene glycol (PEG), namely polymersomes (PSs) that allow for the 
encapsulation of native proteins without the need for any chemical modification. We made 
use of this platform for the development of a vaccine against LASV, focusing our efforts 
towards the development of humoral immunity. We have chosen as a target the viral 
glycoprotein 1 (LASV-GP1), as it is generally accepted that the GP1 of arenaviruses such as 
LASV might be the target of neutralizing antibodies, since it contains the host receptor 
binding site 14. 
We demonstrated that production and loading of LASV-GP1 is feasible, and furthermore we 
showed that humoral responses against this pathogen are elicited in naïve mice.  
Quantitatively, we observed no differences in the antibody response between formulations; 
however, we showed that PSs encapsulation of LASV-GP1 promoted enhanced recognition 
of the virus GP1 when displayed in its native conformation. Furthermore, by employing a 
peptide array we demonstrated that encapsulation broadens the epitope targeting by serum 
antibodies against LASV. These results support the feasibility of the development of a pure 
synthetic subunit LASV vaccine using PSs, offering a safer alternative in immunization.  
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4.3 MATERIALS AND METHODS 
Animals 
C57BL/6 female mice, between 8-12 weeks of age, were purchased from Harlan (France). 
All animal experiments were performed under the approval from the Veterinary Authority of 
the Canton of Vaud (Switzerland) according to Swiss Law.   
LASV-GP1 encapsulation 
PEG-bl-PPS block-copolymers were produced as described in Chapter 3. For the formation 
of PSs with Lassa antigens, a thin-film of copolymer was rehydrated with a solution of 500µl 
at 2 mg/mL of LASV-GP1 or fluorescently labeled LASV-GP1 in 50mM phosphate buffer, and 
rotated for 48hrs at 4°C.  Afterwards, the solution was extruded at least 4 times through 0.2 
µm nucleopore track-etched membranes (Whatman) to obtain PSs ranging between 150 nm-
170 nm, with polydispersity values lower than 0.2. Purification of the PS-loaded from the 
unloaded protein was achieved by size exclusion chromatography through a Sepharose CL-
6B column. Fractions containing PSs were pooled together and further concentrated though 
an Ultra-centrifugal filter (Amicon) with a cutoff of 100 kDa. Final LASV loading was 
estimated by subtracting the amount of the unloaded protein to the starting LASV-GP1 used. 
Using this method, we calculated an average concentration of 432 µg/mL of LASV in the PSs 
solution. The size of PSs was determined by dynamic light scattering with a Nano Zs 
Zetasizer (Malvern Instruments). 
MPLA labelling 
The adjuvant MPLA was labeled on its primary 6’- hydroxyl position by reaction with the 
pentafluorophenol pyrene active ester (PfPy) using pyridine both as base and solution. The 
reaction mixture was heated to 50°C and stirred for 18h. The solvent was then removed 
under reduced pressure, and the product purified from the non-reactive dye by precipitation 
in acetone. 
Immunizations 
All vaccines were administered intradermally (i.d.) into the 4 limbs. 10 µg of LASV-GP1 was 
injected per mouse for all formulations, together with 10 µg of CpG-B (Microsynth), 10 µg of 
MPLA (Salmonella minnesota R595, AvantiLipids) or 50 µg of R848 (Invivogen). Before the 
immunizations, free LASV-GP1 was filtered through a 0.22 µm membrane (Millipore 
Corporation) to remove aggregates. All PSs and proteins batches were tested for endotoxin 
levels using a TLR activation assay based on HEK-Blue reporter cell lines (Invivogen) before 
immunization. 
ELISAS 
For the detection of antigen specific antibodies, 96-well Nunc MaxiSorp® 96-well maxisorp 
plates were coated with 5 µg/mL of LASV-GP1 overnight at 4°C. For the ELISA with the 
purified virus, VSV pseudotypes expressing the Lassa glycoprotein were used for the plate 
coating.  Plates were washed 3 times with PBS/ 0.02% Tween-20 and blocked using a 2.5% 
casein solution in PBS for 2 hours at room temperature (RT). Serial dilutions of serum in 
casein were added to the blocked plates for 2 hrs at RT.  Plates were washed 4 times and 
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mixed with detection antibodies against IgG1, IgG2c, IgG3 or total IgG (Southern Biotech). 
All secondary antibodies were conjugated to horseradish peroxidase (HRP). After incubation 
of 1h at RT, plates were washed 4 times and developed using 50 µL of TMB (eBiosciences). 
The signal was stopped by adding 20µL of 2N H2SO4. Plates were analyzed using a plate 
reader spectrophotometer (Tecan) by measuring the absorbance at 450nm with correction at 
570nm.  
Preparation of lymph node and spleen suspensions 
Lymph nodes were opened with needles and digested in DMEM (1.2mM CaCl2, 2% FBS, 
Pen/Strep) containing collagenase D (500µg/mL). After digestion, lymph node cell 
suspensions were filtered through a 70 µm nylon cell strainer.  For spleen, single cell 
suspensions were prepared by mechanical disruption through a 70µm nylon cell strainer. 
Splenocytes were further treated with hypotonic ammonium chloride–potassium bicarbonate 
buffer to lyse red blood cells.   
Ex vivo restimulation 
Up to 3x106 cells were plated in 96-well plates and cultured in 10% FBS -DMEM medium for 
2 hours at 37°C in the presence of 200 µg/mL of LASV-GP1. As a negative control, we 
restimulated with the Fc portion of the human IgG antibody, in order to make sure that no 
remaining Fc was present in the protein.  For retention of intracellular cytokines, 5 µg/mL of 
Brefeldin A was added to the culture and left for 3 hours. Finally, cells were washed in PBS 
to proceed with staining for flow cytometry.   
Flow cytometry 
Up to 3x106 cells were plated in 96 well plates and washed once with HBSS for staining with 
live/dead fixable cell viability reagent (Life technologies). For surface staining, cells were 
washed once with HBSS supplemented with 0.5% bovine serum albumin (BSA, Sigma) 
(staining buffer) and resuspended in an antibody cocktail using monoclonal antibodies. For 
intracellular staining, cells were fixed and permeabilized with the Foxp3 / Transcription Factor 
Fixation/Permeabilization kit (eBiosciences) according to the manufacturer’s instructions.  
Cells were stained in permeabilization buffer with a cocktail of monoclonal antibodies. After 
staining, cells were resuspended in staining buffer for analysis by flow cytometry. 
Peptide array ( CelluspotsTM ) 
CelluspotsTM (Intavis) slides were blocked with PBS-Tween 0.02% containing 5% milk for 1h, 
followed by 2h incubation at room temperature with mice sera (1/200 dilution in PBS-Tween 
0.02% containing 5% milk). Slides were further washed 3 times (5 min each) with PBS-
Tween 0.02% and incubated with an anti-IgG HRP-conjugated antibody (diluted 1/2000 in 
PBS Tween 0.02%, and 5% milk) for 1h. Finally slides were washed 3 times for 5 min each 
with Tween 0.02% containing and 5% milk. The epitopes were revealed by further incubation 
with SuperSignal™ West Pico Chemiluminescent Substrate (LifeTechnologies) and 
transferred on an X-ray film. 
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Data collection 
Flow cytometry was performed using a CyAnTM ADP (Beckman Coulter) and data were 
analyzed with FlowJo (Tree Star). We used 1-way ANOVA, followed by a Bonferroni post-
test to find differences between the groups. A P value of less than 0.05 was used as an 
indicator of statistical significance.  All data was analyzed using the GraphPad Prism 5 
Software (GraphPad Software Inc., La Jolla, CA). All data presented as bar graphs represent 
the mean ± standard deviation.  
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4.4 RESULTS 
 LASV-GP1-Fc fragment production 
Induction of antibodies targeted against surface receptor binding proteins in viruses is 
particularly attractive as it prevents host cell receptor binding and entry.  
The LASV-GP1 construct was generated by fusing a cDNA fragment containing the codon 
optimized LASV-GP1 sequence (provided by Prof. Erica Ollman Saphire, Scripps Research 
Institute, La Jolla) with human IgG1 Fc by PCR cloning in order to allow for better expression 
in mammalian cells, and also to allow purification via Protein A affinity chromatography from 
cell culture supernatants. The constructs contained an enterokinase (EK) cleavage site 
sequence to allow for the removal of the Fc portion during protein purification (Fig4-1,A).   
 
 
Figure 4–1 Production of the recombinant LASV-GP1. A) Schematic of the LASVGP1-EK-Fc 
construct. B) Purification of LASVGP1-EK-Fc. Supernatants of transfected HEK293T cells were 
subjected to protein A purification. Elution was performed by EK cleavage of LASV GP1-EK-Fc bound 
to the protein A column under neutral pH. The gel shows the Coomassie staining of three eluate 
fractions of LASVGP1 protein after EK cleavage (LASV GP1 F1-3) and three fractions of the Fc 
fragment retained on the protein A column, after acidic elution (Fc fragment F1-3). The LASV GP1 
elutes as a single broad band of 60-65 kDa. C). SDS-PAGE under non-reducing (non reduced) and 
reducing (reduced) conditions of the purified LASV-GP. The extrapolated apparent molecular masses 
are indicated.  
 
Large-scale production of the resulting LASV-GP1-EK-Fc construct was achieved by 
expression in HEK293T cells. After 5 days of culture, the crude supernatants were passed 
though a protein A column for binding to the Fc portion of the protein. After extensive 
washing, the LASV-GP1 was cleaved by adding EK and eluted under neutral pH and 
physiological ionic strength. The EK binding site allowed for the elution of the purified LASV-
GP1 directly from the protein-A column, without the requirement of acidic elution procedures, 
which could have interfered with the native LASV-GP1 conformation. The eluted LASV GP1 
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was generally > 95% pure, as assessed by SDS-PAGE and Commassie blue staining (Fig4-
1, B).  Next, the LASV GP1 was subjected to ion exchange chromatography (IEC) to 
eliminate further impurities and to remove the remaining EK. IEC-purified LASV GP1 was 
then dialyzed against PBS to remove the salts contained in the buffer and concentrated it to 
2 mg/ml for further encapsulation into PSs.  
During the IEC we observed that the purified LASV-GP1 had a molecular weight (MW) 
between 62-64kDa, indicating that the protein exists mainly as a dimer. We corroborated this 
dimeric form by running the protein in reducing versus non-reducing conditions, where a 
band representing the LASV monomer appeared at approximately 34 KDa under reducing 
conditions (Fig4-1, C).  The dimerization likely occurs as a consequence of an unpaired 
cysteine residue present at the N-terminus of the protein.  
 LASVGP1 loads efficiently into Polymersomes 
Our first goal was to determine if LASV-GP1 (LASVGP1 hereafter) could be loaded into PSs. 
For this purpose, we fluorescently labeled LASVGP1 with the AF-594 dye, and mixed 1 mg 
of the labeled protein with 30 mg of the dried PEG-PPS copolymer. After a 48hr incubation 
time at 4°C, we extruded and purified the PSs by gel filtration chromatography. The collected 
fractions revealed that the signal from LASVGP1 was localized in the same fractions where 
PSs routinely elute, indicating antigen loading (Fig4-2, A). To assess that the loaded protein 
was not degraded or damaged during the loading, we dissociated the PSs with PBS/0.5% 
Triton-X100, and analyzed the solution by gel electrophoresis. The protein released from the 
PSs displayed the same MW, close to 70kDa, as the free counterpart (Fig4-2, B). The data 
suggests that no damage has been caused to LASVGP1 during the PSs encapsulation, and 
furthermore, indicates that LASVGP1 encapsulates as a dimer within PSs.  
We measured the size of the PSs loaded with LASVGP1, and found that, on average, PSs 
had a size of 163nm ±7 nm, with a polydispersity index of 0.1 ± 0.05. Thus, we successfully 
formed carriers loaded with the glycoprotein1 from LASVGP1.  
 
 
Figure 4–2 Loading of LASVGP1 glycoproteins into Polymersomes (PSs). A) Left, Schematic of 
the protein encapsulation into PSs. Right, Elution of fluorescently labeled LASVGP1 protein after 
mixing with the PEG-PPS block-copolymers. Signal from the loaded protein appears at earlier 
fractions (8-10), while non encapsulated protein is retained for a longer time in the column, and 
appears at fractions >17.  B) SDS-PAGE gel under non-reducing conditions. Right, the purified 
LASVGP1, left; PS (LASVGP1) after disruption of the vesicles with a solution of Triton X-100.  
74
 Polymersomes loading enhances CD4 T cell responses and humoral responses 
to LASV-GP1 
Several groups have demonstrated that particle-loading both antigen and adjuvant 
synergistically enhances the immune response, since both components drain at similar rates 
and can be targeted to DCs residing at similar locations 15–17. 
We therefore took advantage of the amphiphilic nature of the TLR-4 ligand MPLA for 
entrapping in the PSs during the rehydration of the PEG-PPS polymer. To measure the 
amount of MPLA loaded into PSs, we fluorescently labeled the lipidic molecule as described 
in Fig 4-3. After extrusion and purification, we calculated the amount of MPLA loaded based 
on the fluorescent signal, and found an average of 400µg/mL of MPLA in the PSs. With this 
formulation, we then evaluated the immunogenicity of the LASVGP1 proteins when 
encapsulated in PSs, co-delivered with MPLA formulated or as a soluble compound.  
 
Figure 4–3 Labeling strategy of MPLA. MPLA was labeled with pentafluorophenol pyrene active 
ester (PfPy) for its detection upon loading into PSs.  
 
Mice were immunized two times in three weeks intervals with unformulated LASV or PSs 
containing 10µg of LASV (LASV or PS-LASVGP1, respectively), both in combination with 
10µg of MPLA unformulated or loaded into PSs (MPLA or PS(MPLA)) (Fig4-4, A). After 5 
days, we collected the spleen and draining lymph nodes (LNs), and evaluated the CD4 
responses by an ex vivo restimulation assay, using the purified LASVGP1 as stimulant. As a 
control, we used the human Fc portion, in order to make sure that the CD4 T cell responses 
are indeed targeted to the viral protein, and not to immunogenic Fc fragments that might 
have not be removed by the enterokinase treatment.  
 
There was an enhancement of the CD4 T cell immune response in LNs and spleen in the 
groups where the LASVGP1 was encapsulated, indicating that the immunogenicity of the 
glycoprotein was augmented upon formulation into PSs. As expected, no response was 
produced upon human-Fc restimulation. In the LNs and spleen, PS-LASVGP1 groups 
promoted a 3-fold and 7-fold higher secretion of IFN and TNF by CD4 T cells over the 
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LASVGP1+PS(MPLA) group, and a prominent 20-fold and 10-fold change when either the 
protein or the adjuvant were encapsulated (Fig4-4, B).  
While free LASVGP1 administered with PS-MPLA displayed an enhanced CD4 cellular 
response over the soluble protein and MPLA, the effect was much lower than that observed 
with the encapsulation of the protein. It was also interesting that between the groups where 
LASVGP1 was encapsulated there were no major differences in the immune response. It is 
possible that MPLA also incorporated or adsorbed to the PSs surface after their formation. 
Indeed, when fluorescently labeled MPLA and pre-formed PS were mixed together and 
eluted in a size exclusion column, both components ran together, while MPLA alone without 
PSs displayed a higher retention time in the column (data not shown).  
 
 
Figure 4–4 Intradermal (i.d.) immunization with PS(LASVGP1) conjugates enhance antigen 
specific CD4 T cell responses A) Immunization timeline B) Cytokine secreting CD4 T cells in spleen 
and draining lymph nodes five days after a prime-boost immunization. Lymphocytes were restimulated 
ex vivo with LASVGP1 protein or with the human Fc fragment as a control in the presence of Brefeldin 
A; cytokine expression was assessed by intracellular staining C) LASVGP1 serum antigen-specific 
antibody titers at day 28, one week after the booster immunization.  D) Virus binding of serum 
antibodies at day 28, as a control, we included the serum of mice that received only LASVGP1 protein, 
without adjuvant. L, LASVGP1; M, MPLA. * < p 0.05 ;  **p < 0.01 ; *** p < 0.001 
 

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We also evaluated the humoral responses, and found robust antibody titers in all the 
immunizations (Fig4-4, C). There was a modest increase in the total IgG antibody titer when 
antigen was delivered in the PSs.  Notably, we found a 3-10 times greater IgG antibody 
binding between the PS-LASVG1 and the soluble protein groups when instead of the purified 
protein we used a purified whole virus as antigen during the ELISA assay (Fig4-4, D), 
indicating a better recognition of the LASVGP1 in its native conformation by antibodies 
induced upon protein encapsulation.  Overall, the data suggest that antigen formulation has a 
positive impact on cellular responses, as well as in the quality of humoral responses.  
 Effect of adding multiple TLR adjuvants on the humoral response against 
LASVGP1 
It has been widely reported that multiple TLR ligation actuates synergistically the outcome of 
an immune response16,18–20.  We wanted to evaluate the effect of co-administration of MPLA 
with TLR-7 and TLR-9 agonists on the antibodies against LASVGP1. Therefore, groups of 
mice were immunized with PS-LASVGP1 together with a) 10µg MPLA, b) 10µg MPLA + 
10µg CpG-B, c) 10µg MPLA + 50µg R848 and finally, d) 10µg MPLA+10µgCpG-B+50µg 
R484 (Fig 4-5, A). 
By day 28, one week after the booster immunization, we looked at serum for LASVGP1 
specific IgG antibody titers and IgG antibody isotypes. Compared with our previous 
immunization, this time the free LASV group displayed an enhancement of total IgG titers 
over the PS-LASVGP1. When looking at the effect of the multiple TLR adjuvant formulation, 
we observed that groups containing CpG-B exhibited the highest enhancement in antibody 
titers. In contrast, in the PS-LASVGP1 group, the incorporation of R848 had almost no effect 
on the humoral response (Fig 4-5, B). 
Analysis of the antibody subtypes displayed similar trends to those observed with total IgG, 
although the differences between the free antigen and PS-loaded antigen in the groups with 
two or three adjuvants were more noticeable (Fig 4-5, C).  All the groups displayed high 
IgG2c antibodies, as expected from the Th1-skewing capacity of the chosen TLRs. 
Interestingly, we observed that groups that contained CpG-B had increased IgG3 antibodies, 
although the serum levels of this antibody subclass were generally low.  
We then analyzed the capacity of the serum IgG to recognize the LASVGP1 in its native 
conformation using the whole virus ELISA assay. As observed earlier, the PS loading 
enhanced the recognition of the native glycoprotein over unformulated LASVGP1 (Fig 4-6, 
A). Notably, the only class subtypes able to recognize the LASVGP1 were the IgG2c and 
IgG3 isotypes, while no signal was observed with IgG1 (Fig 4-6, B).  
Finally, in order to determine which regions over the entire LASVGP1 protein were 
recognized by the elicited antibodies, we incubated the immunized serum with a peptide 
array displaying 20mer peptides spanning the LASVGP1 antigen with an offset of 1 
aminoacid. We studied mainly the PS(LASVGP1) immunization adjuvanted with MPLA. 
Antibodies induced upon free LASVGP1 immunization recognized mainly the C terminus of 
the protein. Moreover, PSs promoted that various regions within the LASVGP1 were 
recognized, suggesting that PS loading promoted a broadening of the antibody targeting  
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Overall, the data ratifies that PSs enhanced the quality of the immune response to 
LASVGP1. 
 
 
Figure 4–5 Addition of the unformulated TLR adjuvants to the PS(LASV)-MPLA immunization 
does not enhance the magnitude of the humoral response. A) Adjuvants (doses) used in the 
study. B) End point titers by day 28, one week after the booster immunization. C) LASV-specific IgG 
antibody subtypes at day 28, one week after the booster immunization.  
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Figure 4–6 Virus binding and epitope recognition by serum antibodies elicited after LASVGP1 
and PS(LASVGP1) immunization. A) Total LASVGP1 specific IgG serum antibodies (left) and IgG 
subtypes (right) binding to the virus-ELISA assay. B) Epitope array displaying the regions recognized 
by serum antibodies after administration with single or multiple TLR ligands.  
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4.5 DISCUSSION 
Live attenuated vaccines have been used successfully during the last few decades as 
vaccine platforms 21,22. However, their use in regions where endemic diseases, such as HIV, 
prevail is highly debated since the risk of the vector reverting to a virulent form defeats the 
benefits of vaccination. On the contrary, protein subunit vaccines are a great and safe 
alternative to standard methods of immunization 23. Loading proteins and adjuvants into 
nanocarriers can further increase the effectiveness of subunit vaccines. These carriers drive 
the antigen to lymphoid tissue, enhance DC uptake and increase antigen presentation 24–27. 
Moreover, particulates offer the advantage of homologous prime-boost regime 
immunizations, which is not desired with viral vectors because of the host immune response 
to the proteins of the carrier, which diminishes their effectiveness 28. 
Herein, we demonstrated that the preparation of a stable LASV glycoprotein1 protein is 
feasible. Furthermore, we investigated the impact on the immunogenicity of LASVGP1 after 
loading into PSs. We optimized the vaccine formulation with the TLR-4 adjuvant MPLA, and 
demonstrated that loading into PSs elicited antigen specific CD4 T cellular responses as well 
as robust humoral responses. 
In terms of antibody titers, the PSs encapsulation does not surpass the response induced by 
the soluble protein when administered with MPLA. However, the most important finding is 
that the antigen encapsulated in the PSs platform qualitatively changed the immune 
response in two ways: one, by enhancing the recognition of the LASVGP1 when presented in 
its native conformation; and two, by broadening the serum antibody targeting regions, as 
seen by the increase in peptides recognized by the PS-LASVGP1 serum.  Similarly to our 
previous results, the PSs drove a Th1-like response, characterized by a strong induction of 
serum IgG2c antibodies, and enhanced secretion of IFN and TNF by antigen specific CD4 
T cells. Furthermore, we showed that the antibody subclasses responsible for virus binding 
were the IgG2c and IgG3, which underscore the importance of inducing a Th1-like humoral 
response for a LASV vaccine.  
While the precise mechanism underlying the quality of the humoral response is unknown, we 
speculate that the capacity of the PSs carriers to promote T follicular helper CD4 responses, 
as detailed in our previous chapter, is partially responsible for the observed results. This CD4 
T cell subset provides critical signals to B cells in order to initiate somatic hypermutation and 
affinity maturation, therefore their increased number could augment survival signals for B 
cells and thus sustain their differentiation into long lived plasma cells or memory B cells 29 . 
Instead, in the soluble protein the Tfh cell numbers could have been a limiting factor, thus 
only few B cell clones could survive.   
Interestingly, in our system the addition of TLRs had little effect on the total serum IgG titers 
in the groups when LASV was delivered within PSs, while modestly enhanced serum titers in 
the LASV free group.  However, it is important to note that CpG-B and R848 were not 
formulated into particulates for these experiments, and thus it is likely that the antigen and 
the adjuvant did not target the same antigen presenting cells simultaneously when LASVGP1 
was encapsulated. For instance, Kasturi et al. 15 reported that a dual TLR vaccine enhanced 
memory B cell responses due to signaling through TLR receptors on the same B cells, which 
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is likely not happening in our system, since all the adjuvants used varied in their molecular 
weights and thus, in their lymphatic drainage and cell targeting. Nevertheless, we observed 
that the addition of TLRs further diversifies the antibody repertoire, in agreement with 
previous reports 30, although it happened uniquely when LASVGP1 was delivered within PSs. 
These results suggest that the antigen encapsulation is a crucial parameter for enhancing 
the quality of humoral responses, and also indicates that the response can be further 
improved by formulating additional adjuvants into PSs.   
In summary, we have demonstrated the feasibility of developing a safer subunit vaccine 
based on the PS platform against a neglected disease as Lassa fever. We are currently 
evaluating the protective capacity of our vaccination by employing a pseudotyped viral 
challenge, using the LCMV-Lassa glycoprotein chimeras described recently by Sommerstain 
et al. 31. Furthermore, we are trying to formulate novel TLR7 agonists into PSs in order to 
determine if adjuvant formulations allow for further amplification of the immune response.  
 
 
 
  
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Chapter 5  
Lymphatic endothelial cells scavenge and 
process exogenous antigen in vivo under 
steady and inflammatory conditions 
 
Marcela RINCON RESTREPO, Efhtymia VOKALI, Sachiko HIROSUE and Melody 
SWARTZ  
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5.1 ABSTRACT 
Recently there have been described “atypical” modes of antigen presentation by non-
hematopoietic cells. In this study, we demonstrated that lymph node lymphatic endothelial 
cells (LN-LECs), one of main subsets of stromal cells in LNs, selectively internalized and 
processed foreign exogenous antigen in vivo, both during non-inflammatory and 
inflammatory conditions. Interestingly, in lymphangiogenic LNs LECs displayed a higher 
uptake of antigen, indicating that, similar to classical antigen presenting cells, LECs can 
actively sense and integrate dangerous extracellular signals, and thus augment antigen 
internalization. We assessed whether by interfering with the development of LN 
lymphangiogenesis by blocking the signalling through VEGFR3 we could gain some insights 
into the effects of proliferative LECs on adaptive immune responses. However, in our studies 
we could not demonstrate an effect of blocking VEGFR-3 in reducing LN lymphangiogenesis, 
perhaps due to the usage of other signaling receptors to promote LEC proliferation. Thus, we 
suggest that future studies to evaluate the functional roles of stromal cell presentation in 
adaptive immune responses should be evaluated with more specialized animal models, 
involving lymphatic-specific conditional ablation of components of the antigen presentation 
machinery, that will allow a better understanding of the consequences of antigen scavenging 
by LECs on vaccine-elicited immunity.   
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5.2 INTRODUCTION 
Lymphatic endothelial vessels represent the port of entry of migratory cells, solutes and 
peripheral antigens that drain from distal sites to lymph nodes (LNs)1. LNs are highly 
structured organs that enhance adaptive immune responses by facilitating the interactions 
between peripheral solutes and antigen presenting cells (APCs), as well as the encounter of 
APCs with circulating lymphocytes 2,3.  This is achieved thanks to the LN stroma architecture, 
composed of a heterogeneous population of non-hematopoietic cells that play important 
roles in cell trafficking, LN compartmentalization and antigen distribution 4. The main LN 
stromal cell subsets are distinguished based on their expression of podoplanin (gp38) and 
CD31 on fibroblastic reticular cells (FRCs, gp38+CD31-), lymphatic endothelial cells (LECs, 
gp38+ CD31+), blood endothelial cells (BECs, gp38-CD31+) and a group of double negative 
cells (DN, CD31-gp38-) 5,6.  
Recently, cumulative evidence indicates that stromal cells in LNs not only represent a 
passive scaffold, but also can play active roles in the regulation of adaptive immunity. For 
instance, FRCs and LECs can express and present peripheral tissue restricted antigens 
(PTAs) to CD8 T cells, leading to CD8 T cell tolerance 6,7. Moreover, Lund et al. recently 
showed that antigen presentation is not only restricted to PTAs, since LECs in tumor draining 
LNs scavenge and cross-present antigens derived from the tumor. In this scenario, the 
atypical antigen presentation by LECs led to the induction of CD8 T cells that were 
dysfunctional and apoptotic 8, suggesting that the interactions between LECs and CD8 T 
cells have mainly tolerogenic outcomes. 
It has been widely observed that during various inflammatory events such as viral infections, 
subunit immunizations and during cancer, there is a noticeable increase in LEC proliferation 
in draining LNs, which is termed LN-lymphangiogenesis8–12. The main modulators of LN-
lymphangiogenesis are members of the VEGF family of growth factors. Among the most 
important factors are VEGF-C and VEGF-D, which signal through VEGFR-3, a tyrosine 
kinase receptor whose expression is restricted to the lymphatic endothelium in adults. 
LN-lymphangiogenesis was proposed as a mechanism to restore LN homeostasis after an 
inflammatory challenge by supporting lymphocyte egress13. However, there is limited 
information about the active role of proliferative LECs during an immune response.  It was 
recently reported by Tamburini et al. that LECs can capture antigen during viral infections14. 
Notably, this antigen was stored for long periods of time in LECs, which positively correlated 
with antiviral CD8 T cell responses.  What was most interesting was the fact that antigen 
storage appeared only during inflammatory conditions, and happened only in proliferative 
LECs. However, in these experiments, the author did not find antigen processing by LECs, 
and thus these cells played mainly a passive role, serving as a “depot” of antigen, perhaps 
for maintaining a pool of memory CD8 T cells.    
Herein, we wanted to evaluate whether LN-LECs can scavenge and process foreign 
exogenous antigens in inflammatory and non-inflammatory conditions. For this purpose, we 
delivered intradermally (i.d.) different macromolecules to naïve mice, or mice pretreated with 
the TLR-9 ligand, CpG-B, that drives a potent inflammatory response.  We showed that LN-
LECs internalized and processed soluble Ovalbumin (OVA) 90 minutes after i.d. 
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administration, while 70KDa and 2000KDa Dextran remained excluded from the LEC 
population, being mainly taken up by macrophages.  
Furthermore, we sought to evaluate which were the implications of antigen uptake by 
proliferative LECs during a subunit immunization in the outcome of adaptive CD8 T cell 
responses. For this purpose, we administered the antibody mF4-31C1, which blocks the 
signaling through VEGRF-3 and affects uniquely proliferative LECs 15, after the immunization 
with Nanoparticles OVA, together with CpG-B. We demonstrated a modest, although not 
significant reduction in the number of LN-LECs upon VEGFR3 treatment. However, there 
were not significant differences in the cellular composition of LNs, or any changes in the 
overall distribution of stromal cells. Consequently, analysis of adaptive immune responses 
also revealed no significant changes in the numbers and phenotype of expanding CD8 T 
cells. Although we do not discard the possibility that lymphatic proliferation might have an 
effect on adaptive responses, we conclude that the effect of solely blocking the VEGFR-3 
pathway is either too small to be observed in our system, or there is a compensation of other 
signalling pathways that promote LEC expansion. We therefore conclude that evaluation of 
the immunomodulatory effect of LN lymphangiogenesis in vivo should involve selective in 
vivo models, or dual blocking therapy with anti VEGFR-3 and anti VEGFR2, since 
inflammatory lymphatic expansion is dependent on signalling through both receptors. 
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5.3 MATERIALS AND METHODS 
Animals 
C57BL/6 female mice, between 8-12 weeks of age, were purchased from Harlan (France). 
OTI mice were obtained from an in house colony. All animal experiments were performed 
under the approval from the Veterinary Authority of the Canton of Vaud (Switzerland) 
according to Swiss Law.   
Nanoparticle preparation 
For NP-ss-Ovalbumin preparation, 500µL of NPs previously activated with pyridyl disulfide 
(as described in Chapter3) were mixed with 286.6 mg of guanidine hydrochloride (GndHCl) 
to achieve a final concentration of 6M of GndHCl. The solution was filtered through a 0.22µm 
membrane (Millipore Corporation) and mix with 50µL of OVA at 40mg/mL.  The mixture was 
left overnight at room temperature, and then purified by size exclusion chromatography 
through a Sepharose CL-6B column equilibrated in PBS. The concentration of OVA in the 
fractions obtained after purification was determined by a BCA assay following the 
manufacture’s instructions (ThermoScientific). Before and after the coupling, the size of NPs 
was determined by dynamic light scattering with a Nano Zs Zetasizer (Malvern Instruments). 
The diameter of NPs varied between 35nm-40 nm. 
Immunizations and adoptive transfers 
All vaccines were administered i.d. into the 4 limbs. 10 µg of OVA conjugated to NPs were 
injected per mouse, together with 10 µg of CpG. Before the immunizations, OVA was filtered 
through a 0.22µm membrane (Millipore Corporation) to remove aggregates. All PSs and 
proteins batches were tested for endotoxin levels using a TLR activation assay based on 
HEK-Blue reporter cell lines (Invivogen) before immunization. For the blockage of LEC 
proliferation, either 500 µg (i.p.) or 100µg (i.d.) of -VEGFR-3 neutralizing antibody (mF4-
31C1, ImClone/Eli Lilly) or IgG control were administered one day before immunization, 
followed by two extra doses, three days apart between each administration.  
For the adoptive transfer of naive antigen specific T cells, single cell suspensions were 
prepared from spleens of OTI mice. CD8 T cells were isolated using the EasySep™ Mouse T 
Cell Isolation Kit (Stemcell Technologies). Immediately after isolation, 1x106 cells were 
adoptively transferred i.v. into naïve host mice.  
In vivo antigen drainage and immunostaining 
To determine whether LN LECs can actively capture antigens in vivo, fluorescently labeled 
OVA protein was administered into the limbs of mice and its distribution within various cells in 
the LN was analyzed after 90 min. C57BL/6 mice were injected intradermally (i.d.) with 15 µg 
OVA-AF647 in the limbs. After 90 min, mice were transcardially perfused with a heparinized 
saline solution containing 1 g/l glucose and 20 mM HEPES (pH 7.2). For immunostaining, 
brachial LNs were removed and fixed overnight in 1% paraformaldehyde in PBS (pH7.4). 
After three washes in PBS, LNs were embedded in a block of 2% agarose and sectioned 
(150 µm) using a vibratome (Leica). Sections were blocked in 0.5% of casein and further 
labeled using Abs against CD3 (BD Pharmingen) and Lyve-1 (Reliatech). Images were 
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acquired on a Leica SP5 confocal microscope using an immersion 20x or 63x objective and 
processed using Imaris software (Bitplane). 
Preparation of lymph node and spleen suspensions 
Lymph nodes were opened with needles and first digested in DMEM (1.2mM CaCl2, 2% FBS, 
Pen/Strep) containing collagenase IV (1mg/mL) and DNAse I (40µg/ml) to isolate 
lymphocytes. In a second digestion step in DMEM with collagenase D (1mg/mL) and DNAse 
I (40µg/ml), stromal lymph node cells were isolated for further analysis. After digestion, 
lymph node cell suspensions were filtered through a 70µm nylon cell strainer.  For spleen, 
single cell suspensions were prepared by mechanical disruption through a 70µm nylon cell 
strainer. Splenocytes were further treated with hypotonic ammonium chloride–potassium 
bicarbonate buffer to lyse red blood cells.   
Ex vivo reestimulation 
Up to 3x106 cells were plated in 96-well plates and cultured in 10%FBS -DMEM medium for 2 
hours at 37°C in the presence 200µg/mL of OVA. Afterwards, 5 µg/mL of Brefeldin A were 
added to the culture and left for 3 extra hours.  
Flow cytometry.  
Up to 3x106 cells were plated in 96 well-plates and washed once with HBSS before staining 
with live/dead fixable cell viability reagent (Life technologies). For surface staining, cells were 
washed once with HBSS supplemented with 0.5% bovine serum albumin (BSA, Sigma) 
(staining buffer) and resuspended in an antibody cocktail using monoclonal antibodies. For 
intracellular staining, cells were fixed and permeabilized with the Foxp3 / Transcription Factor 
Fixation/Permeabilization kit (eBiosciences) according to the manufacturer’s instructions.  
Cells were stained in permeabilization buffer with monoclonal antibodies. After staining, cells 
were resuspended in staining buffer for analysis by flow cytometry.  
Data collection 
Flow cytometry was performed using a CyAnTM ADP (Beckman Coulter) and data were 
analyzed with FlowJo (Tree Star). We used the non-parametric Mann-Whitney U test for 
statistical comparisons. A P value of less than 0.05 was used as an indicator of statistical 
significance. All data was analyzed using the GraphPad Prism 5 Software (GraphPad 
Software Inc., La Jolla, CA).  All data presented as bar graphs represent the mean ± 
standard deviation.  
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5.4 RESULTS 
 Lymphatic endothelial cells capture antigen according to its physicochemical 
properties under steady state conditions 
There is increasing evidence of the potential of stromal cells as antigen presenting cells. For 
instance, our group has recently shown that in tumor bearing mice, lymph node (LN) LECs 
presented tumor associated antigen to CD8 T cells, promoting proliferation and cytokine 
secretion by the activated cells 8. Motivated by these studies, we wanted to determine 
whether antigen scavenging by LECs in vivo occurred also under steady state conditions, out 
of the tumor context, and how this uptake varied for antigens with different properties.  
To evaluate the in vivo antigen uptake by LECs, fluorescently labelled Dextran and Chicken 
egg Ovalbumin (OVA) protein were used as model antigens. We injected 15µg of lysine 
fixable dextran (70KDa and 2000KDa), alone or together with 15µg of fluorescently labelled 
OVA intradermally (i.d.) into the upper limbs of naïve mice. After 90 min, we collected the 
brachial draining LNs, and analysed them by confocal microscopy for colocalization with 
Lyve-1, a marker almost exclusively found in LECs. 
 Already 90 min after administration, all the antigens were observed in the draining LNs 
(Fig5-1). We took a closer look of the lymphatic sinuses region, which is enriched with LECs, 
and found that in these areas most of the OVA protein was surrounded by Lyve1+ structures. 
The elongated shape of the Lyve1+ structures indicated that they undoubtedly correspond to 
LECs, and not macrophages that also express Lyve1 (Fig1A, top left).  
 
Figure 5–1 Antigen uptake by lymphatic endothelial cells in steady state conditions. Confocal 
images of brachial lymph nodes 90 minutes after intradermal (i.d.) administration of fluorescently 
labelled antigen (15µg). 
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Instead, the signal from both types of dextran was excluded from the LEC cytoplasm, and 
was most likely associated with macrophages lining the subcapsular sinuses, as reported in 
previous studies 16,17 (Fig5-1, top middle and right). The same results were obtained 
independently of whether Dextran (70KDa) was co-administered with OVA (Fig5-1, bottom 
left) or given alone (Fig1, middle and right). In order to evaluate if the antigen observed 
inside LECs was also being processed, we injected i.d. DQ-OVA, and analysed LNs 90 min 
after administration. DQ OVA is heavily labelled with a fluorophore that is autoquenched 
when the protein structure is intact, but that fluoresces upon proteolytic digestion. Indeed, we 
observed processing of OVA inside various LECs, as well as other populations in the 
subcapsular sinus, which could be macrophages (Fig5-1, bottom right) 
 Uptake of foreign protein antigen occurs in steady state and inflammatory 
conditions. 
There is little information about LEC antigen uptake in vivo under inflammatory conditions, 
outside of the tumor context. We therefore wondered whether antigen uptake happens also 
in LNs that have been previously inflamed by the administration of a large dose of the TLR-9, 
CpG-B. We had previously observed that administration of this adjuvant promotes a marked 
cellular expansion in draining LNs, characterized by the proliferation and remodelling of the 
lymphatic architecture (LN-lymphangiogenesis).  
 
 
Figure 5–2 OVA uptake by lymphatic endothelial cells in draining lymph nodes in steady state 
conditions and inflammatory conditions. A) Left, experimental set up; right, confocal images of 
brachial lymph nodes 90 minutes after intradermal (i.d.) administration of fluorescently labelled OVA in 
naïve or CpG-B treated mice. B) Flow cytometry analysis of the OVA uptake by LECs (CD31+ gp38+) 
in naïve and CpG-B treated mice.  
 
Mice received 30µg of CpG-B in the left and right side of the upper back, since this location 
also drains to the brachial LNs. Four days after, we injected fluorescently labelled OVA 
(15µg) i.d. in the upper limbs, and 90 min later collected brachial LNs for analysis by confocal 
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imaging and flow cytometry. As a comparison, we used mice that received saline instead of 
CpG-B (Fig 5-2). 
The images clearly revealed that also under inflammatory conditions antigen was indeed 
taken up by LECs, similarly to the steady state condition. OVA was found in the cytoplasm of 
LECs, and this was true for all the regions of the LN analysed (Fig5-2, A).  Analysis by flow 
cytometry also revealed that there was an increase in the frequency of OVA+ LECs in 
inflamed LNs (Fig5-2, B), suggesting that LECs, similarly to classical APCs, may also sense 
and integrate exogenous dangerous signals, and thus augment antigen internalization. 
 Administration of -VEGFR3 during the course of an immunization does not 
have a significant impact on lymph node composition or lymphocyte activation 
Most of the current studies about antigen presentation by LECs indicate that this subset is 
strongly tolerogenic. In tumors, our group has previously observed that reducing 
inflammatory lymphangiogenesis upon administration of an -VEGFR3 antibody (R3 
hereafter) enhances the CD8 T cell antitumoral response 8. In our studies, we wanted to 
determine whether this happens also in the context of a subunit immunization.   
We decided to use the nanoparticle vaccine platform established in our laboratory, since with 
this system we can induce larger numbers of antigen specific CD8 T cells when compared to 
the free OVA, thus making it easier to detect potential changes happening upon the 
administration of the blocking antibody. Furthermore, these carriers can be also taken up by 
LECs, and the internalized antigen can be crosspresented to CD8 T cells 18.  
We administered 3 doses (3 days apart) of 500µg or R3 or IgG control, starting at day -1. At 
day 0, we vaccinated mice with NP-ss-OVA (10µg) together with 10µg of CpG-B, and at day 
6 we evaluated draining LNs. As an extra control, we had a group that was not immunized, 
and did not receive an antibody treatment (Fig5-3, A).  
Analysis by confocal imaging revealed no major differences in the lymphatic architecture in 
LNs between the IgG and the R3 treated groups (Fig5-3, B). We only observed a reduction 
of Lyve1+ structures within medullary sinuses in the R3 treated mice, although this is only a 
qualitative observation, and its verification would require further analysis.  Next, we studied 
by flow cytometry the numbers of LN-LECs after the diverse treatments, based on the 
expression of CD31 and gp38 (Fig5-3, C).  
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Figure 5–3 Intravenous -VEGFR3 treatment has no effect on the cellular composition of 
draining lymph nodes after a subunit immunization.  A) Immunization and antibody treatment 
timeline. B) Confocal images of brachial LNs at day 6 after the immunization with NP-ss-OVA and 
CpG, under IgG or -VEGFR3 treatment. C) Left, Identification of stromal cells (CD45-) based on the 
expression of gp38 and CD31; right, LECs counts at day 6. D) Weight of individual lymph nodes after 
immunization and antibody treatment. E-F) Frequency of CD45- and CD45+ cells (% of viable cells) in 
draining lymph nodes at day 6. G) Frequency of cytokine secreting CD8 T cells; lymphocytes were 
restimulated ex vivo with SIINFEKL peptide in the presence of Brefeldin A; cytokine expression was 
assessed by intracellular staining.  
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The data show that the immunization promoted lymphangiogenesis and LN expansion, as 
described by the increment in LECs numbers and LN weight (Fig5-3, C-D). However, there 
were no differences between the antibody treated groups, suggesting that the R3 blockade 
did not inhibited LN-lymphangiogenesis. There were also no differences in the cellular 
composition of draining LNs between the two treated groups. We analyzed the stroma 
population, (which lack the CD45 antigen, Fig5-3, C) and found no major differences in the 
CD45- cell compartments, i.e., FRCs, BECs and LECs (Fig 5-3, E). Regarding the number of 
lymphocytes, both IgG and R3 groups induced the same changes on the B cell and T cell 
populations upon vaccination when compared to the untreated control (Fig5-3, F).  
Next, we investigated if there were differences in CD8 T cell responses in draining LNs, as 
well as in the spleen.  Herein we also included a control group that was immunized but did 
not received any antibody treatment, in order to evaluate if there were unspecific effects 
induced by the type of antibody administrated. We observed that the functionality of CD8 T 
cells was not affected, and all mice displayed the same capacity to secrete inflammatory 
cytokines upon an ex-vivo restimulation assay with SIINFEKL (Fig 5-3, G). 
 
 
Figure 5–4 -VEGFR3 treatment has not effect on the expansion and phenotype of adoptively 
transferred OTI CD8 T cells after a subunit immunization. A) Immunization and antibody treatment 
timeline. B) Frequency of Thy1.2+ OTI cells at day 7 after intradermal (i.d.) immunization with NP-ss-
OVA and CpG-B, under IgG or VEGFR3 treated conditions. C-D) Phenotype of Thy1.2+ OTI cells in 
draining lymph nodes and spleen, based ton the expression of killer cell lectin-like receptor G1 
(KLRG1) and the interleukin-7 (IL-7) receptor alpha chain (CD127) 19. Memory precursors cells 
(MPECs) are defined as CD127+ KLRG1-, while short lived effector cells (SLECs) are defined as 
CD127-KLRG1+ . 
 
We had comparable results using an OTI adoptive transfer system (Fig5-4, A). We observed 
a similar expansion of OTI cells on day 7 after the immunization, regardless of the antibody 
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treatment that the mice received (Fig5-4, B).  We also analyzed the phenotype of the 
Thy1.2+ OTI cells, based on the expression of killer cell lectin-like receptor G1 (KLRG1) and 
the interleukin-7 (IL-7) receptor alpha chain (CD127) 19, which defines CD127+ KLRG1- as 
memory precursors effector cells (MPECs), and CD127-KLRG1+ as short lived effector cells 
(SLECs).  OTI cells displayed no differences in none of the markers studied, suggesting that 
in the short term, the treatment with R3 has no effect on the induction of adaptive CD8 T 
cell responses (Fig5-4, C-D).  These results were not surprising, considering that there was a 
no significant reduction in the numbers of LECs upon R3 treatment.  
 Intradermal delivery of VEGR3 does not significantly affect the stromal 
composition of LNs and the number of antigen-specific CD8 T cells induced after 
nanoparticle immunization 
Finally, we sought to study whether delivering the R3 antibody intradermally could have a 
more significant effect on the reduction of LN-lymphangiogenesis, since this delivery route 
targets effectively the LNs. For this purpose, we injected 25µg of R3 or IgG control on the 
back on the mice, since this location also drains to brachial LNs, and thus it does not 
interferes with the drainage of the NP-ss-OVA immunization, which is administered in the 
foot pad. Similarly to our previous studies, we gave three doses of antibody three days apart. 
Mice were immunized one day after the first R3 or IgG dose, and draining LNs were 
evaluated on day 6 (Fig5-5, A). We observed no significant differences in the weight of LNs, 
as well as no changes in the overall frequency of FRCs and LECs (Fig 5-5, B-C). Although 
we observed a reduction in the LEC counts in the R3 treated mice, this was not significant 
compared to the IgG control group (Fig5-5, D).  Staining with a pentamer recognizing 
SIINFEKL-MHCI revealed also no differences in the frequencies of antigen specific CD8 T 
cells (Fig5-5, E) in the LN.  In conclusion, the administration of the R3 antibody 
intradermally does not change the functional outcomes of CD8 T cell adaptive immunity after 
a NP-based immunization.   
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Figure 5–5 Intradermal administration of -VEGFR3 does not inhibit lymph node 
lymphangiogenesis.  A) Immunization and antibody treatment timeline. B) Weight of individual LNs 
after immunization and antibody treatment. C) Frequency of Follicular reticular cells (FRCs) and 
Lymphatic endothelial cells (LECs) , from the total stromal population (CD45-). D) LEC counts on day 
6 after the NP-ss-OVA immunization. E) Frequency of SIINFEKL antigen specific CD8 T cells in 
draining LNs. 
  
96
5.5 DISCUSSION 
Lymph node stromal cells were once thought to provide only a support for antigen and 
cellular trafficking. However, we now know that these subsets play active and important roles 
in shaping immune responses and maintaining immune tolerance.  
Herein, we have reported that under steady state LECs take up the exogenous antigen 
Ovalbumin (OVA) in vivo. The consequences of scavenging in steady state conditions were 
addressed recently in our group by Hirosue et al. 18, who demonstrated that antigen 
presentation by LECs led to CD8 T cells that were dysfunctional and apoptotic in vitro. We 
used fluorescently labelled OVA to show that under inflammatory conditions LECs also 
scavenged antigen, even at higher rates than those observed under steady-state conditions. 
In fact, recent studies have shown that LECs express pattern recognition receptors (PPRs), 
such as Toll like receptors (TLRs) 20,21, which in classical APCs enhance antigen uptake and 
cross-presentation.  Thus, active sensing of dangerous signals in the extracellular 
environment could have enhanced the antigen scavenging by LECs under inflammatory 
conditions. It is still not determined which receptors LECs use to internalize antigen, although 
Hirosue et al. 18 reported that both macropinocytosis and clathrin mediated endocytosis were 
necessary for OVA uptake by LECs in vitro. 
The fate of the antigen after internalization remains still unknown for us. A transcriptional 
analysis of stromal cells after stimulation with Escherichia coli, LPS and OVA showed that 
this treatment led to the overexpression of MHCI and MHCII by LECs 21. Thus, a fraction of 
the antigen may have been processed for its presentation to T cells in order to contribute to 
the maintenance of peripheral tolerance. While some antigen may be stored within the LECs, 
as described by Tamburini et al., it would be interesting to study whether the internalized 
protein can be also transferred to other APCs, such as DCs, similarly to what has been 
described between B cells and follicular dendritic cells 22.  
We also show that once internalized, OVA was processed inside LECs. This is in agreement 
with early observations by Sixt et al., that observed by confocal microscopy signal from DQ-
OVA, similarly to what we have seen in our experiments 16.  However, recently Tamburini et 
al. reported no DQ-OVA signal, and thus, no processing of the antigen that was archived by 
LECs after a viral infection or a subunit immunization 14.  The discrepancies between this 
study and ours are likely arising from the two different timelines between the experiments, 
since Tamburini studied antigen signalling/processing one week post immunization.   
To date there is no information on the active role of LECs in modulating immune responses 
during inflammatory conditions. Therefore, we assessed whether by interfering with the 
development of LN lymphangiogenesis we could gain some insights into the effects of 
proliferative LECs on adaptive immune responses. For this purpose, we administered the 
mF4-31C1 antibody that blockades signaling through VEGFR3, affecting the growth of new 
LECs, without disturbing the functionality of pre-existing vessels 15.   
However, we did not observe significant differences in the numbers of LECs upon -
VEGFR3 administration. Similarly, there were no significant changes in the weight of the LNs 
between the VEGFR3 and IgG control groups, and lymphocyte and stroma composition in 
LNs were very similar in both groups. We discard the possibility that the absence of any 
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obvious phenotype was because of the lack of activity of the antibody, since the same 
compound has been widely used in our group to block the development of 
lymphangiogenesis in VEGF-C overexpressing tumors8.  
A potential cause of the unnoticeable effects is that a) under CpG-B administration the 
inflammatory lymphangiogenesis depends mainly on other growth factors or b) LECs are 
compensating the lack of VEGFR3 signalling with additional growth factors. It has been 
noted that during inflammation macrophages, neutrophils and B cells can secrete VEGFA 
and VEGFD, which signal through VEGFR2, and that are recognised to be potent inducers of 
lymphangiogenesis 23–26. Moreover, it has been suggested that the fully processed form of 
VEGF-C can also signal through VEGFR-2 24. Considering both scenarios, it is then not 
surprising that there were no noticeable effects of the blockade of VEGFR3 signalling.    
Examination of adaptive immune responses also failed to show an effect of the blockade of 
the VEGFR3 signalling on the induction of CD8 T cell responses, as well as in their 
functionality, when compared to the isotype control. This was observed in endogenous CD8 
T cell, and also when the response was magnified upon adoptive transfer of OVA specific T 
cells. The results are not surprising, considering that no remarkable changes in the LEC 
population were observed after administration of the -VEGFR3 antibody.  
Considering that only 1% of the LN population corresponds to the stromal cell subset, we 
speculate that assessing the specific role of LECs in vivo will require more specialized animal 
models, such as the ones where Cre-recombinase is expressed in LECs under the control of 
Lyve1 and Prox1 promoters. In this way, lymphatic-specific conditional mutations can be 
developed, and the role of antigen presentation by LECs in adaptive immunity could be more 
easily addressed.  Moreover, future studies could also involve dual blockade of -VEGR3 
and -VEGFR2 signalling, as reported by Tan et al. and Angeli et al. 12,13, since in this setup 
the two main signalling receptors of LECs can be blocked, and the probabilities of observing 
a more significant reduction of LEC numbers are higher. 
Overall, this work demonstrated that LECs do sense and integrate signals from their 
microenvironment in steady state and inflammatory conditions. Future work is necessary to 
understand the consequences of LEC scavenging of foreign exogenous antigens on vaccine-
elicited immunity.  
  
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Chapter 6  
Conclusions, implications and future directions 
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6.1 CONCLUSIONS 
In this thesis we explored the use of nanocarriers as antigen vectors for the development of 
subunit vaccines.  We assessed their efficacy when delivered together with TLR ligands on 
modulating the magnitude and quality of cellular and humoral responses against the model 
protein OVA, as well as peptides and proteins derived from real pathogenic viruses, such as 
the LCMV and LASV.  
Initially, we have confirmed the efficacy of PEG-PPS NPs to generate high frequencies of 
cytotoxic T cell responses when delivered together with the TLR9 ligand CpG-B.  Moreover, 
we achieved a deep characterization of the phenotype of the elicited CD8 T cells, and 
demonstrated that the NPs generated a durable immunity, promoting long-lasting memory T 
cells that persist in lymphoid and non-lymphoid organs, suggesting that intradermal 
immunization with NPs has the potential to generate a broad protection to pathogens with 
diverse tissue tropism.  
In the following study, we studied two nanocarrier platforms, PSs and NPs, in order to 
understand the mechanisms by which these two vectors preferentially activate CD4 or CD8 T 
cell responses. We demonstrated that the size of the nanocarrier, together with the mode of 
antigen loading, impacts the intracellular trafficking of the antigen, as well as its localization 
in lymphoid organs upon in vivo administration.  We further assessed the consequences of 
having antigen in PSs or NPs on humoral immunity. We showed that PSs enhance 
significantly the number of T follicular helper CD4 cells, a subset that is a crucial component 
in B cell-based vaccines.  Thus, these studies highlight the potential of PSs as a vector for 
the development of vaccines aimed to elicit antibodies.  
Indeed, in our following chapter, we demonstrated that the quality of the cellular and humoral 
response against an antigen derived from LASV is dramatically enhanced by the PSs 
platform. The PSs increase the number of epitopes recognized by serum antibodies, thus 
enhancing the recognition of the viral protein when displayed in its native conformation. We 
thus confirm the potential of PSs for the development of B cell vaccines, and moreover, 
proved the feasibility of developing nanoparticle-based vaccine against an important, 
although neglected diseases, Lassa fever.  
Finally, we demonstrated that not only professional APCs capture antigen delivered 
intradermally. We showed that lymphatic endothelial cells do capture antigen in vivo during 
steady state and non inflammatory conditions. We envision that the understanding of the 
implication of antigen scavenging by stromal cells will bring novel methods of 
immunomodulation that can be directly applied for tuning the outcome of adaptive immune 
responses.  
To conclude, we have proved that NPs and PSs are effective vectors for the development of 
subunit vaccines, and moreover, we accomplished our aims to establish new insights and 
immediately applicable guidelines for the development of rationally designed vaccines.  
103
6.2 IMPLICATIONS AND FUTURE DIRECTIONS 
 Establishing correlates of protection for T cell-based vaccines 
The development of T cell memory is a key component for the success of T cell-based 
vaccines. Memory T cells are comprised of subsets that vary in important properties such as 
cytotoxic activity, trafficking patterns, tissue residence and proliferative capacity. Establishing 
which of these subsets is promoting protective capacity has been an intense subject of 
research. Our group has developed and applied the PEG-PPS nanoparticle technology in 
therapeutic and prophylactic T cell based vaccines. This antigen carrier has proven to be 
effective in promoting protection against influenza, as well as reducing tumor burden, thus 
providing enhanced host survival in a melanoma murine model 1,2. However, the question 
that remains open after these studies are: how did the NP vaccines mediate protection or 
enhanced survival?  
T cell phenotype is commonly used as a surrogate of protection.  Herein, we made use of an 
adoptive transfer system to characterize in deep the phenotype of T cells after the 
nanoparticle vaccination. We demonstrated that a prime boost immunization with a peptide 
derived from the LCMV promotes a large memory pool of T cells that hold an effector 
phenotype characterized by a large population of CD43- CD27- cells, which also lack the 
expression of CD62L and CD127, and display high levels of KLRG-1. This subset was found 
in large frequencies in the spleen, as well as in peripheral organs such as lung and liver.  
Thus, it might be possible that previous studies involving NPs could have mediated 
protection or enhanced tumor killing because of the capacity of this vector to elicit effector 
memory T cells. Indeed, there is cumulative evidence that the effector memory subset, 
previously believed to be “senescent”, has important roles in protective immunity 3–6. What it 
is interesting in these studies are the mechanisms by which the effector subset contributed to 
protection. For instance, Olson et al. 3 demonstrated that the T effector memory cells were 
better in protecting against Listeria monocytogenes thanks to an enhanced cytotoxic activity 
of the effector subset, combined with their strategic position in the red pulp of the spleen, 
which is likely the main point of encounter between cytotoxic lymphocytes and Listeria 
infected cells.  Hansen et al. 5 also demonstrated that protection against a simian 
immunodeficiency virus (SIV) by a viral vector that promoted effector memory CD8 T cells 
was acknowledged to the location of T cells in the surface of mucosal tissues, which helped 
to impaired virus replication early during infection,  thus avoiding disease dissemination.  
Overall, what these studies suggest is that is the combination of various factors, such as T 
cell functionality, tissue residence and T cell magnitude, that will determinate the protective 
capacity of T cell memory. However, considering the broad tissue tropism of pathogens, it is 
likely that for each disease a correlate of protection has to be determined.  Therefore, our 
future work will be focus towards understanding how the effector memory cells obtained after 
an NP immunization vary in their protective capacity when compared to the central-memory 
like cells obtained upon the DC vaccination, in an acute and a chronic model of LCMV, as 
well as in a bacterial challenge model with Listeria monocytogenes. Moreover, we aim to 
evaluate the impact of other TLR adjuvants on the T cell memory phenotype. The overall 
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goal is to be able to tailor the immune response elicited by the NPs to the desired immune 
outcome that is beneficial for each pathogen. 
 Polymersomes as a promising system for B cell vaccines: applications for a 
vaccine against Lassa fever 
For most of vaccines approved to date, the success of the immunization depends on the 
ability of the vector to elicit neutralizing antibodies against the microbial agent.  However, 
eliciting neutralizing antibodies is not always an easy task, as is the case for HIV and 
influenza, which have proven to be major challenges for the vaccinology field.  
In our third chapter, we evaluated potential mechanism by which the PS platform enhances 
CD4 T cell responses over the NP platform. We observed that PSs protected the antigen 
from endosomal escape and deliver it to lysosomes, which are specialized compartments for 
MHCII loading.  This had direct implications on the numbers of antigen specific CD4 T cells. 
Moreover, a large proportion of the CD4 T cells elicited displayed an enhanced T follicular 
helper phenotype. These results are very promising, since development of immunizations 
that favor Tfh differentiation is an important goal in B cell-vaccine development. For instance, 
results from last phase III clinical trial of HIV (RV 144) have demonstrated that HIV-infected 
individuals that make broadly neutralizing antibodies (bnAbs) have a higher frequency of 
CD4 T follicular helper cells in blood than those who did not make bnAbs7. In fact, we have 
demonstrated that the implementation of the PSs platform for the development of a vaccine 
against the surface glycoprotein 1 from Lassa leads to a broadening of the serum antibody 
targeting regions. In the context of an infection, this indicates that these antibodies will be 
able to recognize and fight more strains of Lassa. This is crucial for a future vaccine against 
Lassa fever, since more than 54 strains of LASV have been identified in West Africa. Among 
these strains there is a high genetic diversity, especially in the glycoprotein precursor (GPC, 
encoding for GP1 and GP2) 8,9, and thus elicited antibodies with a broad targeting spectrum 
will be a crucial component of a successful vaccine candidate.  
Our current studies are focus on a) evaluating the protective efficacy of the antibodies 
elicited upon PS-LASV immunization and b) optimization of the adjuvant platform, in order to 
further modulate the humoral immune response to LASV-GP1. In our first study, we will 
challenge mice with a chimeric LCMV strain expressing the glycoprotein of LASV 10. This 
strain has a similar kinetic persistence than the clone-13 of LCMV. Hence, we aim to 
evaluate if the antibodies elicited upon a PS-LASV immunization could avoid the 
establishment of a chronic viral infection. Secondly, we are currently working on the 
encapsulation of TLR7/8 and TLR9 ligands on PSs for their codelivery with PS-LASV.  We 
could then evaluate if the delivery of immunomodulatory signals in nanoparticle carriers can 
simultaneously target the same APC as the antigen and thus enhance the quantity as well as 
the quality of the antibodies elicited. 
 Capture of antigen by LECs: Implications for adaptive immunity 
With the aim to understand the active role of lymphatic endothelial cells (LECs) in adaptive 
immunity, we evaluated the capacity of these cells to capture antigen in vivo. We used 
steady state conditions to prove the LEC scavenge antigen in steady state and inflammatory 
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conditions. In steady state, we have proven that the crosspresentation of exogenous 
antigens leads to T cell dysfunction and tolerance in a PD-L1 dependent manner 11. In vivo, 
the role of LEC scavenging in an inflammatory environment still needs to be elucidated.  We 
hypothesize two potential outcomes for this uptake: First, based on the strong evidence of 
the tolerogenic nature of the stromal cell subsets, we believed that an active antigen 
presentation in MHCI and MHCII complexes might drive T cell tolerance. This could be a 
mechanism of protection, as previously described for FRCs, in order to counterbalance the 
immune response and avoid T cell-mediated immunopathology, and thus, excessive damage 
of the lymphoid architecture 12.   
In a second scenario, antigen uptake by LECs can also promote immunity, although not 
directly by presenting processed antigen to T cells. As described by Tamburini et al., 13 
antigen archiving by proliferative LECs was beneficial for the maintenance of T cell memory. 
Considering the close location of LECs with DCs, it is also possible that the scavenged 
antigen is transferred to lymph node resident DCs for its further presentation to T cells, in 
order to initiate an early immune responses 
 Nanoparticle-based vaccines: promising vectors for programming the quality of 
the immune response 
Herein we have demonstrated the potential of nanocarriers as future components of subunit 
vaccines. Even though there is strong evidence indicating the efficacy of synthetic 
nanoparticles for vaccination purposes, it would take several years until a synthetic vaccine 
can be approved for their use in humans, as most of the current companies based on 
nanoparticles are currently in Phase I studies 14. However, we believe that in the future 
nanoparticles will offer a potent system of antigen delivery with a good safety profile, which is 
indeed needed in the context of various vaccine candidates, specially those targeting people 
in zones of high prevalence of endemic diseases. 
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